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1. Overview on atherosclerosis 
 
Atherosclerosis is one of the leading causes of death in the developed world and consists in 
a chain of chronic multistep inflammatory events that lead to formation of a hard structure 
called “plaque”. Atherosclerotic plaques could represent a risk factor in the development of 
thrombotic events that can cause heart attack and stroke [1]. 
The first description of atherosclerosis dates back to 1755, when the Swiss anatomist 
Albrecht von Haller proposed the term “atheroma”, from Greek “athere”, in describing any 
kind of gruel materials which composed the plaques that he had analyzed [Haller, Albrecht 
von. Observatio XXXXVII: materia ossium morbosorum. In: Opuscula pathologica. 
Lausanne: Bousquet; 1755. p. 124–8.]. Thus, he used the term “atheroma” to describe 
mellow plaques and he studied them in various stages, from the softer and yellowish 
plaques to the harsher and calcified ones. 
The German-French surgeon Johann F. Lobstein coined the term “arteriosclerosis” in 1833 
to describe the stiffening (hence “scleros” i.e. hardening) of the arterial wall due to 
atherosclerosis. He noticed that only some area of arterial tree was affected by this 
particular disease, in particular the aortic arch and its branches [Lobstein JGCFM. Traités 
d’anatomie pathologique. Paris: Chez F.G. Levrault; 1833. p. 550–3]. 
In 1904, the German pathologist Felix Jacob Marchand, by combining the terms 
“atheroma” of von Haller and “arteriosclerosis” of Lobstein, minted the term 
“atherosclerosis” which represents a subtype of “arteriosclerosis” that involves primarily 
the intima and innermost part of the media of medium-sized and large arteries [Marchand 
JF. Über arteriosklerose (athero-sklerose). Verh Kongresses Innere Medizin. 1904;21:23–
59]. 
The first pathological theory regarding the atherosclerosis was described in the mid-19th 
century by Karl von Rokitansky, who thought that atherosclerosis began with deposition of 
fibrin and other blood elements in the intima layer, which resulting degeneration, along 
with cholesterol crystals and fatty globules depositions, led to atheroma formation. In the 
same years, Rudolf Virchow proposed another theory, whereby the inflammation in the 
intima of arterial wall would be the major mechanism of plaque development and that the 
fibrous thickening evolves as a consequence of a reactive fibrosis induced by proliferating 
connective tissue cells [2].  
The number of proposed theories on the pathogenesis, after these first descriptions, has 
gradually grown. Another theory proposed in the first decades of 1900 was the “lipid 
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hypothesis” which suggested that some diet constituents were involved in plaque 
formation, pointing out the importance of cholesterol as the major atherosclerotic risk 
factor. This theory led to “response-to-retention hypothesis” proposed by Williams and 
Tabas, which suggested that the augmentation of plasmatic LDL(s) was responsible of 
their retention in the inner arterial wall, where they are more susceptible to oxidation, 
triggering the inflammatory processes responsible for the development of atherosclerotic 
lesions [3]. In the last decades of 20th century, molecular biology studies furnished a new 
pathological theory, called “hypothesis of lesion reaction” which was proposed for the first 
time by Ross and Glomsett in 1976 [4]. They proposed that the atherosclerotic lesions were 
the result of focal injury to arterial endothelium, followed by adherence, aggregation and 
release of platelets. Since then, numerous studies have followed to define the causes and 
the molecular details of endothelial dysfunction. 
To date, all of these main theories (inflammatory-, lipid- and lesion reaction-hypothesis 
i.e.) are closely linked to each other and not mutually exclusive in explaining the 
pathogenetic events which lead to atherosclerotic plaques formation.  
 
2. The structure the arterial blood vessels 
 
Arteries of medium and large caliber, responsible for blood transport from the heart to all 
body compartments, consist of three layers [5] (Figure 1). From vessel lumen to the outside 
we found: 
 
- Tunica intima: the thinnest layer which consists a monolayer of endothelial cells 
(ECs), the endothelium, above the basal lamina, a thin layer of loose connective tissue, 
and a sub-endothelial elastic lamina. The ECs play a pivotal role in integrity and 
function maintenance of vessel wall: they exert a barrier function, by producing a wide 
range of factors that regulate cellular adhesion, thromboresistance and vessel wall 
inflammation [6]. Moreover they control blood pressure by releasing vasoconstrictors 
or vasodilators and the trafficking of different kinds of agents which could participate 
in preliminar phases of atherosclerotic plaque formation. Internal elastic lamina, which 
is fenestrated to ensure nutritive substances from blood to reach the tunica media, and 
collagen fibers (and fibroblasts) of the basal lamina participate to vessel elasticity. 
 
- Tunica media: the thickest layer made of a connective stroma of collagen fibers which 
sustain concentric elastic fibers and smooth muscle cells (SMCs), which in turn 
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synthesize elastic fibers and collagen. SMCs, which contain contractile actin fibers, 
tend to be longitudinally aligned and are strictly associated with collagen fibers. The 
elastic fibers, interposed between the SMC, are relatively extensible and responsible of 
blood pressure maintenance, by allowing contraction (during diastole) and distension 
(during systole) of the artery wall during a cardiac cycle. 
 
- Tunica adventitia: the outermost layer made of a fibrous connective tissue, which 
mostly contains SMCs, fibroblasts and, in larger vessels, nervous plexuses and 
lymphatic vessels. It is necessary for protecting the other layers below and allows 
them to be fixed to the surrounding tissues. In the largest arteries, such as aorta, this 
tunica is perfused by a system of small blood vessels, called vasa vasorum, that 
provide nutriments to the adventitia itself. 
 
 
Figure 1: Structure of an artery (Image from Servier Medical Art - http://www.servier.com/Powerpoint-image-bank) 
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3. Atherosclerotic plaque development 
 
In the development of atherosclerotic lesions, we can distinguish several stages: the initial 
processes that generate lesions clinically silent; the stages of the progression leading to the 
formation of a stenosis not necessarily symptomatic; the complicating events, at last, that 
are the basis of the clinical chronic or acute manifestations. 
It is noteworthy that clinical onset of atherosclerotic lesions could have large variability 
due to the prevalence of one of these three main processes, which will be discussed below: 
1) the accumulation of lipids in the sub-endothelium of the arteries 2) the establishment of 
an inflammatory status by infiltration of lymphocytes and macrophages which, engulfing 
lipids accumulated, become foam cells 3) migration and proliferation of smooth muscle 
cells (SMCs) with production of extracellular matrix [7]. Consequently, some 
atherosclerotic lesions appear predominantly dense and fibrous, whilst others can contain 
large amounts of lipid and necrotic debris, while most of them are the result of 
combinations of both characteristics.  
 
3.1  Initial steps of atherosclerosis 
 
The earliest events of atherosclerosis take place in the endothelium, the intima layer of 
artery walls. Normally an healthy endothelium exerts its antiatherogenic duty through the 
regulation of vascular tone and homeostasis, smooth muscle cells proliferation, platelet 
aggregation and adhesion, leukocyte migration, thrombosis and thrombolytic events [8]. 
Particularly, endothelial cells synthesize a wide range of autocrine and paracrine 
substances: for example, nitric oxide (NO), prostacyclin and histamin are involved into 
vasodilation while angiotensin, endothelin and serotonin are vasoconstrictors. The 
antithrombotic activity of endothelium is exerted through the secretion of antiaggregatory 
molecules, such as NO and prostacyclin, anticoagulatory molecules, (heparin and heparan 
sulfate), and through activation of fibrinolysis, by secretion of tissue plasminogen activator 
(t-PA) and plasminogen activator inhibitor-1 (PAI-I) [9]. 
It is evident that numerous biological pathways cooperate in ensuring vascular homeostasis 
and even a partial loss of their functionality can lead to endothelial dysfunction. The risk 
factors that contribute to the initial dysfunctions of atherosclerosis can be divided into two 
categories: systemic and hemodynamic. Among systemic factors, we find unchangeable 
risks, such as age, gender, race, heredity and changeable risk factors, such as hypertension, 
high cholesterol, hyperhomocysteinemia, smoke, obesity and physical inactivity. The 
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hemodynamic factors which contribute to endothelial dysfunction will be further 
discussed. 
These pathological states are associated to pro-inflammatory stimuli and to the increase in 
oxidative stress, in particular, through the production of reactive oxygen species (ROS) 
[10]. High ROS levels cause a decrease in NO availability, which leads to vasoconstriction, 
smooth muscle cells proliferation and migration, platelet aggregation and leukocyte 
adhesion, all events that underlie plaque formation. Moreover low NO levels may induce 
caveolin 1-dependent oxidation of LDL cholesterol, which in turn inhibits endothelial NO 
syntase (eNOS) activity, causing a further reduction of NO synthesis [8]. LDL modification 
not only involves ROS but also other enzymes, such as myeloperoxidase which generates, 
from hydrogen peroxide and chloride, high levels of hypochlorous acid, that causes a 
further oxidation of lipoproteins [11]. Oxidation of LDL is known to be, along with 
endothelial dysfunction, one of the pivotal mechanisms of atherosclerotic plaque 
formation. Particularly, changes in the endothelial cells permeability cause a 
subendothelial retention of atherogenic cholesterol-containing LDL (Figure 2A) and 
numerous evidences suggest a tight link between high levels of circulating LDL and their 
accumulation, by a passive diffusion through EC tight junctions, in the subendothelial 
matrix [12]. LDL retention, mediated by interaction between LDL apoliprotein b (Apo 
B100) and matrix proteoglycans, predispose them to oxidative modification [13]; Oxidized 
LDL (oxLDL) in turn stimulate endothelial cells to produce adhesion molecules, such as 
Vascular Cell Adhesion Molecule 1 (VCAM-1) and Intercellular Adhesion Molecule 1 
(ICAM-1), chemotactic molecules, such as Monocyte Chemoattractant Protein-1 (MCP-1), 
and growth factors, such as Macrophage Colony-Stimulating Factor (M-CSF)[14,15]. This 
“activated” status of endothelial cells mediate transmigration of T lymphocytes and 
monocytes through luminal endothelium in the intima. Here, monocytes proliferate and 
differentiate into macrophages (Figure 2B). The latter adopt a pro-inflammatory phenotype 
and encode a wide range scavenger receptors (LOX-1 and CD36 needed for oxLDL 
uptake) which in turn are stimulated by macrophages-produced cytokines, such as tumor 
necrosis factor α (TNFα) and interleukin-1β (IL-1β) [16]. This pro-inflammatory condition 
induces macrophages to constantly adsorb oxLDLs until they become like “foam cells” and 
their accumulation in the intima layer lead to fatty streaks formation (Figure 2B). 
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Figure 2: Atherosclerotic plaque formation. Alteration of endothelial cells permeability promotes lipids infiltration and 
accumulation (A). Monocytes from blood flow penetrate into the intima, differentiate in macrophages and internalize 
lipids, forming foam cells (B). In response to pro-inflammatory cytokines and MMPs secretion, VSMCs proliferate and 
migrate (C), secrete extracellular matrix which form the fibrous cap of atheroma (D) [17].  
 
3.2 Progression of atherosclerotic lesion and advanced lesions 
 
Recruitment of smooth muscle cells (SMCs) from tunica media is involved in plaque 
formation, too (Figure 2C). Numerous growth factors (EGF, PDGF, TGF, VEGF) and 
hormones, such as Angiotensin II, activate uncontrollably the SMCs and they switch from 
a quiescent phenotype to a migratory and synthetic one. These “active” SMCs secrete high 
levels of metalloproteinases (MMPs), which promote SMCs migration from the media into 
the intima via degradation of SMCs’ membrane degradation [11]. Moreover, under the 
influence of cytokines and growth factors secreted by foam cells and T cells, SMCs 
synthesize extracellular matrix (ECM) proteins, resulting in pathogenic vascular 
remodeling and intimal stiffening [18,19]. 
These ECM molecules, including interstitial collagen and elastin, form a fibrous cap that 
covers the plaque and overlies macrophage-derived foam cells, some of which die by 
apoptosis and release lipids that accumulate in extracellular space. In the early stages of 
atherosclerosis the removal of apoptotic macrophages (efferocytosis), is efficient and 
stimulates production of anti-inflammatory cytokines, such as interleukin-10 (IL-10) and 
transforming growth factor-β (TGF-β). Vice versa in advanced lesions efferocytosis is 
compromised and necrotic macrophages, cellular debris and extracellular lipids form a 
lipid-rich pool called necrotic core (Figure 2D) [20]. The balance between fibrous cap and 
necrotic core influences the rupture of the plaques. It has been seen that caps of ruptured 
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plaques have high density of macrophages and a large lipid core topped by a thin fibrous 
cap [21]. Moreover, in lipid-rich plaque an important role is assumed by T lymphocytes, 
which elaborate high levels of interferon γ (IFN-γ). INF-γ inhibits SMCs proliferation and 
collagen synthesis, making plaques more prone to rupture. Conversely, stable plaques have 
a thick fibrous cap over a small fatty core and are rich in collagen. Thus, it is clear that two 
remodeling factors may operate during lesion formation: on one hand, SMCs stabilize the 
plaque by producing connective tissue preventing plaque rupture and, on the other hand, 
macrophages and T cells elaborate enzymes and cytokines respectively that weaken the 
plaque framework [22,23].  
Plaque staibility may be influenced by calcification and neovascularization, processes 
which characterize advanced lesions.  
Calcification, which reflects more stable lesions [24], consists in a gradual accumulation of 
mineral deposits, expecially hydroxyapatite, on death cells and extracellular lipids [25]. 
Moreover, in these plaques cell attachment proteins (osteopontin), proteins associated with 
calcium (osteonectin), and γ-carboxylated proteins that regulates mineralization 
(osteocalcin) were identified. Watson KE et al. demonstrated that TGF-β and 25-
hydroxycholesterol stimulate bone morphogenetic protein-2, a powerful factor for 
osteoblastic differentiation, suggesting that calcification is a regulated process similar to 
bone formation [26].  
Neovascularization consists in the growth of small vessels inside the plaque itself, 
mechanism highly influenced by inflammatory mediators and hypoxic signals. Monocytes 
and T-cells secrete factors such as fibroblast growth factor (FGF) and vascular endothelial 
growth factor (VEGF) that actively contribute to angiogenesis and, in turn, along with 
other cytokines (IL-6, MCP-1, TNF-alpha i.e.) and angiogenic factors (angiopoietin-2), 
stimulate inflammation and intraplaque hemorrhages, causing plaque instability and 
rupture [27,28]. 
 
3.3 Complications of atherosclerotic lesions 
 
The evolution of the atherosclerotic lesions is extremely variable, so all the phenomena 
described for initial and late stages of atherosclerosis development may be more or less 
constant. Atherosclerosis’ last event is plaque rupture: the exposure of tissue factor (TF) to 
blood flow leads to coagulation cascade activation with recruitment of platelets and 
inflammatory cells. The interaction between exposed atheroma tissue debris, platelet 
receptors and coagulation factors leads to the formation of a thrombus which may 
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compromise the arterial lumen, hindering blood flow in situ [29]. Some of these thrombi 
can detach from lesion site and, following the blood flow, can reach a branching site of a 
small vessels, blocking the blood flow.  
Atherosclerosis does not have any clinical onset until an internal lamina is 40% clogged 
with plaque and symptoms depend on which arteries are affected.  
The occluding stenosis are usually characteristic of the late stage of the plaque evolution. 
The effects of the reduction of blood inflow to the tissues, are more or less serious 
depending on whether the supply of oxygen is absent or reduced. 
The most common complications of atherosclerosis are: 
 
1. Coronary artery disease: it consists in an ischemic process involving the arteries that 
supply blood to the heart, resulting in i) angina pectoris, chest pain due to insufficient 
oxygenation of myocardium ii) myocardial infarction, an injury due to blood flow 
impairment in an area of the heart iii) heart failure, when heart is unable to pump 
blood to all body districts. 
2. Carotid artery disease: carotid arteries supply blood to the brain and their narrowing 
can cause i) stroke, a sudden loss of brain function due to ischemia and symptoms 
may include speech and breath impairment, loss of vision and coordination, severe 
headache and paralysis ii) transient ischemic attack (TIA), due to a temporary blood 
supply deficit in a small area of brain causing a momentary loss of neurological 
skills. 
3. Peripheral artery disease: it involves narrowing of major arteries that supply blood to 
the arms, legs and pelvis. Usually the main clinical events are pain and numbness but 
if artery occlusion is extreme, it leads to tissue death (gangrene). 
 
Along with these complications, there are other minor atherosclerotic events that may 
involve kidneys (renal artery stenosis), sex organs (erectile dysfunction), eyes (eye stroke) 
and abdomen (mesenteric ischemia). 
Lastly, another complication is the aortic aneurysm, due to the collapse of vessel wall 
resulting in an abnormal dilatation of aorta, especially in the abdominal region. Aneurysm 
rupture is the most dangerous event that could happen with consequent internal bleeding, 
eventually resulting in death [30]. 
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4. Shear Stress: hemodynamic forces and molecular pathways 
 
 
As previously described, the endothelium can be considered as a thin barrier between 
blood flow and vessel wall and, therefore, it is exposed to different hemodynamic forces. 
Particularly it is exposed to three different forces: i) shear stress, which is the tangential 
frictional force of the flowing blood on the endothelium, and his magnitude is expressed in 
units of force per unit area (Newtons per square metre or Pascals or dynes per square 
centimetre; 1 N/m
2
 = 1 Pa = 10 dyn/cm
2
), ii) cyclic strain, the transumural force acting on 
the vessel wall, due to the pulsatile nature of blood flow and iii) hydrostatic pressure, the 
force that blood exerts on the vessel walls (Figure 3) [31]. 
 
 
Figure 3: Hemodynamic forces. Scheme of principal forces acting inside the blood vessels (adapted from Chatzizisis et 
al. [32]) 
 
It has been well studied that endothelial cells are sensitive to those hemodynamic forces 
and, through mechanotrasduction, they convert a mechanic stress into a biological 
pathways, responsible for maintenance of vascular homeostasis. This process involves a 
wide range of mechanosensors (ion channels, receptors for tyrosine kinase, G protin-
coupled receptors, junction proteins, integrins and membrane lipids i.e.) so that they under 
intensive study to understand the normal and pathological biochemical signals that they 
could generate [33]. 
Contextually to atherosclerosis, the geometric structure of the arterial tree has a pivotal role 
in regulating the hemodynamic forces which in turn modulate activation of 
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mechanosensors. In particular, shear stress has a critical role in determining where 
atherosclerotic plaques could form [34–36]. Endothelial SS (ESS) patterns are determined 
both by the pulsatile nature of blood flow in arteries and by the geometric structure of the 
vessels. Principally, in straight areas of vascular tree, the blood flow is laminar and the 
ESS is pulsatile and unidirectional (magnitude: 15-70 dyne/cm
2
), whereas in geometrically 
irregular regions, such as curves and branches, the blood flow becomes disturbed and 
underlies Low and Oscillatory ESS (LO ESS). Low ESS, which occurs at the inner areas of 
curvatures, as well as upstream of stenoses, is unidirectional and with a fluctuating 
magnitude, resulting in a low time average (magnitude <10 to 12 dyne/cm
2
) [32]. 
Oscillatory ESS, which occurs primarily at the lateral walls of bifurcations, in the vicinity 
of branch points and downstream of stenose, is bidirectional with a very low magnitude 
between systole and diastole (close to 0 dynes/cm
2
) (Figure 4).  
   
Figure 4: Definition and example of laminar (pulsatile) and low and oscillatory shear stress (Image from Chatzizisis et 
al. [32]) 
 
The link between ESS patterns and localization of atherosclerotic plaques was 
demonstrated for the first time in 1969 by Caro et al. [37] and, since then, numerous ex 
vivo/in vivo investigations and computational fluid dynamic simulations were carried on in 
the last years, showing that some areas of arterial tree subjected to LO ESS were more 
prone to plaques development [38–43]. These findings are supported by in vitro data 
Low and oscillatory ESS
(<10-12 dyne/cm2)
- Direction: Bidirectional (oscillatory)
- Magnitudine: low time-avarege
Cross-section
Laminar ESS
(15-70 dyne/cm2)
- Direction: Uniderctional
- Magnitudine: physiological time-avarege
Blood flow
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showing that endothelial cells cultured under low shear stress show high ROS levels, 
whereas high, laminar shear stress is protective, inhibiting apoptosis. [44,45]. 
Moreover, still today, numerous studies are conducted with the aim to define the shear 
stress patterns during systolic and diastolic phase of a cardiac cycle: in “linear” areas of the 
vasculature, where laminar shear stress occurs, during systole, the highest values of shear 
stress magnitude are reached, whereas during diastole the magnitude values are lower but 
still positive, indicating that in these districts blood flow is always arranged in ordered 
laminar patterns and his pulsatile nature causes only a variation of shear stress magnitude 
into a high-protective range. At the areas with a complex vascular geometry, such as the 
aortic arch, blood flow is organized in separated flow patterns and, as previously 
mentioned, LO ESS occur. Here, the shear stress exhibited remarkably lower and 
oscillatory values in systole as compared with that in diastole, favoring atherosclerosis 
onset and progression. Since the early studies correlating the position of the human carotid 
plaque and LO ESS [46], the relevance of these studies lies in the fact that elevated heart 
rate, increasing the relative time spent in systole, as compared to diastole, would increase 
the exposure of areas prone to plaque development to the most atherogenic shear stress 
patterns [47,48]. 
Numerous studies seem to indicate that LO ESS has a cardinal role in all the steps towards 
atherosclerotic plaques formation: 
- LO ESS stimulates LDL retention within the subendothelial area, by enhancing 
endothelial cells turnover and altering tight junctions between cells, resulting in more 
LDL infiltration [33]. Moreover, low ESS enhances the espression of LDL receptor by 
activating sterol regulatory elements binding pronteins (SREBPs), a process mediated 
by integrins [49] 
- Unidirectional ESS stimulate NO production, through eNOS gene expression and 
protein activation, leading endothelial cells to a more physiological condition. 
Conversely LO ESS inhibits NO production and stimulates other vasoconstrictors, such 
as endothelin-1 [50,51]. Moreover, NO bioavailability is decreased by high ROS levels 
(as a result of an increased NADPH oxidase gene expression), which augments 
oxidative stress and LDL oxidation [52]. This inflammatory status leads to the 
activation of adhesion molecules (VCAM-1, ICAM-1) chemotactic molecules (MCP-1) 
and cytokines (TNF-α, IL-1 and IFN-γ) which sustain atherosclerosis progression. 
- LO ESS promotes SMCs migration from media to intima via ECMs degradation 
through upregulation of pro-inflammatory stimuli, which stimulate MMPs synthesis by 
macrophages.  
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- LO ESS-mediated IFN-γ inhibits ECMs synthesis by SMCs and contemporarily 
induces SMCs apoptosis, sustained by TNF-α, IL-1β, affecting plaque stability [53].  
- Downregulation of eNOS e t-PA genes mediated by LO ESS increases plaque 
instability which, along with a simultaneous accumulation of platelets near the region 
of vascular wall subjected to low ESS, enhances thrombi formation [54]. 
- LO ESS promotes neovascularization by upregulating VEGF expression [55] and other 
angiogenic factors (angiopoietin-2 [56]). Along with increased inflammation, oxidative 
stress and MMPs synthesis, it enhances plaque instability. 
- Bone morphogenic protein 2 and 4 (BMP2/4), which participate in plaque calcification, 
are upregulated in atherosclerotic lesions, and their inhibition reduces vascular 
calcification and atherosclerosis [57]. It has been seen that LO ESS stimulates BMP4 in 
ECs, inducing NADPH-mediated ROS production which, as previously described, 
enhances atherosclerotic lesion progression [58]. 
 
The evaluation of these pathway, along with the hemodynamic studies of the forces acting 
inside the artery vessels, could be a new diagnostic approach in identifying risk factors 
involved in development of atherosclerotic events [59]. 
 
5. Ivabradine: a pure heart rate-reducing molecule 
 
Resting heart rate (HR) is regulated by spontaneous depolarization of sinoatrial node 
myocytes. These cells don’t have a true resting potential, but they generate spontaneous 
action potential. The depolarization is sustained by voltage-sensitive membrane mixed 
Na
+
-K
+
 inward current, namely the current funny (If), which was first described in the late 
1970s and has been widely characterized in the last decades [60,61]. 
Pacemaker activity makes funny channels an obvious target for new drugs aiming at 
regulation of heart rate. The research on these drugs has become of great interest in light of 
the fact that the link between elevated heart rate and cardiovascular events is well 
established in patients with cardiovascular disease [62,63]. 
The amplitude of If current determines the slope of the diastolic depolarization phase and 
thereby the HR. Ivabradine ({7,8-dimethoxy 3-propyl}1,3,4,5-tetrahydro-2H-3-
benzazepin-2-one) (Figure 5) decreases HR by specific and selective binding of 
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, particularly HCN4 
isoform, which generate the If current in the sinus node, slowing the diastolic 
depolarization slope without affecting blood pressure or cardiac contractility [64–66]. 
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Ivabradine blocks If channels by interacting with them from the intracellular side, when 
they are in open state, indicating that it acts in current-dependent manner, since when the 
channels are closed it cannot reach its binding site [67]. 
 
 
Figure 5: Ball-and-stick model of ivabradine molecule. N: Nitrogen; O: Oxygen. The structure is taken from 
ChemSpider. 
 
Recent studies have demonstrated a protective effect of ivabradine on the vasculature 
(reviewed in [68]). In mouse models of mild (hApoB+/+ [69]), or severe (LDLr-/- 
hApoB+/+ [70]; ApoE-/- [71;,72;,73;,74]) dyslipidemia, ivabradine prevented endothelial 
dysfunction in several vascular beds (aorta, coronary, renal and cerebral arteries). 
Furthermore, ivabradine was able to reduce aortic plaque area in ApoE-/- [71;,73] and 
LDLr-/- hApoB+/+ [70] mice models of atherosclerosis fed a western diet.  
The vascular effects of ivabradine were associated with a reduction of vascular oxidative 
stress (decrease of NADPH oxidase activity [71;,74] and eNOS uncoupling [74]), decrease 
of pro-inflammatory chemokine MCP-1 [71] and of AT1-R expression [74]. Ivabradine’s 
vascular effects are not the consequence of a lipid-lowering activity, since the drug did not 
alter cholesterol and triglyceride levels [69;,71;,74]. Additionally, at therapeutic relevant 
concentrations, ivabradine ex vivo (i.e. directly incubated with isolated arteries) had no 
effects on normal vascular physiology [69]. Interestingly, the in vivo beneficial effects of 
ivabradine on endothelial dysfunction could not be reproduced ex vivo [69;,71]. Taken 
together, these results indicate that a direct effect of ivabradine on vessels is unlikely, and 
suggest that the reduction of heart rate could be the primary mechanism of action of the 
drug. 
In cynomolgus monkeys with elevated heart rate, coronary artery atherosclerotic lesions 
were more than twice as extensive as their lower heart rate littermate [75]. In young post-
O 
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myocardial infarction patients, a significant correlation was found between heart rate and 
severity and progression or coronary atherosclerosis [76]. In accordance with these 
observations, the reduction in resting heart rate by metoprolol, a beta-blocker, slows 
endothelial cell replication (a marker of dysfunction/activation) in psychologically stressed 
cynomolgus monkeys [77], while the reduction in resting heart rate by surgical ablation of 
the sinoatrial node slows the atherosclerotic process in the cynomolgus monkeys fed a high 
fat diet [78;,79]. 
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AIM OF THE STUDY 
 
Data from the literature support the detrimental effect of elevated heart rate in the 
pathogenesis of atherosclerotic plaques which are prone to develop in the arterial regions 
characterized by disturbed flow.  
Numerous studies demonstrated that ivabradine limits atherosclerotic plaques formation in 
animal models. The mechanism of this protection is still unknown. It has been 
hypothesized that as heart rate decreases, following ivabradine treatment, the diastolic 
phase increases, thereby decreasing the exposure time of aortic arch endothelium to 
systolic flow, which is characterized by a more atherogenic low and oscillatory shear stress 
(Figure 6).  
 
 
 
 
Figure 6: Schematic representation of systolic and diastolic phase during a cardiac cycle. Ivabradine 
treatment (orange arrow) does not alter the systole (red bars) but prolongs the diastole (green bar). 
 
The aim of this study was to determine the molecular effect of a short-term treatment with 
ivabradine in the initial steps of atherosclerosis development in an in vivo model of severe 
dyslipidemia (ApoE deficient-mouse) fed a standard diet. 
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2) MATERIALS AND METHODS 
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1. Mice and ivabradine treatment 
 
C57BL6/J and ApoE deficient mice were purchased from Charles River Laboratories 
(Wilmington, MA, US). In our animal facility, all animals were exposed to a semi-natural 
light cycle of 12:12 and were caged at room temperature (21-23 °C) with 55-60% of 
humidity. During the 6 days of acclimatation, all animals received water at libitum. At day 
7 water was changed to ivabradine solution (15 or 30 mg/kg/day – Servier, France) for 
treating ApoE-/- mice. All animal studies were carried out according to the guidelines of 
the European (86/609/EEC) and the Italian (D.L.116/92) laws and after approval by the 
local ethical review panel of University Animal House and by the Italian Ministry of 
University and Research.  
 
- Endothelial enriched-RNA extraction studies: preliminary experiments to determine 
the yield and the quality of RNA extraction from endothelium of mice aortic arches 
were conducted on ten 10-weeks old C57BL6J mice. Five 10-weeks old C57BL6/J 
mice were sacrificed to extract RNA from the whole aorta. Seven 10-weeks old 
C57BL6/J mice were sacrificed for qRT-PCR analysis of Notch components   
- Time course experiment: sixteen 5-weeks old ApoE -/- mice were sacrificed when 
they reached the age of 6 (n=4), 7 (n=4) , 8 (n=4) and 10 (n=4) weeks. 
- Test ivabradine dose: to establish the exact dose of ivabradine treatment, ten 5-weeks 
old ApoE-/- mice, after one week acclimatation, were treated for one week with 15 
mg/kg/day (n=5) or with 30 mg/kg/day (n=5) of ivabradine. 
- Main experiment: twenty two 5-weeks old ApoE -/- mice, after one week acclimation, 
were randomly assigned them to four treatment groups receiving 1) 30 mg/kg/day of 
ivabradine for two weeks (n=9), 2) 30 mg/kg/day of ivabradine for four weeks (n=9), 
3) and 4) no treatment for two (n=2) and four weeks (n=2). 
- En-face studies: for endothelial dysfunction studies thirteen 5-weeks old ApoE -/- 
mice were sacrificed when they reached the age of 10 (n=4), 18 (n=4) and 25 (n=5) 
weeks (no ivabradine treatment). Five 5-weeks old ApoE-/- mice, after one week 
acclimation, were treated for nineteen weeks with ivabradine (30 mg/kg/day) and then 
sacrificed when they reached the age of 25 weeks. For en-face analysis of Hes5 protein 
levels ten 5-weeks old ApoE-/- mice, after one week acclimation, were randomly 
assigned them to 2 treatment groups receiving 1) 30 mg/kg/day of ivabradine for four 
weeks (n=5) and 2) no treatment for 4 weeks. Eight 10 weeks old C57BL6/J mice were 
sacrificed for en-face analysis of Notch components. 
19 
2. Heart rate measurement 
 
Animals were not anesthetized during this procedure to avoid interferences with ivabradine 
treatment. To avoid stress which could affect heart rate, at least 2 days before heart rate 
measurement, mice chest was shaved at third and fourth intercostal space, next to the 
sternum. Mice were handled carefully, taking them from the neck and placed with head up. 
Heart rate was monitored by Doppler echocardiography (Vivid ECG, GE Healthcare 
Worldwide) and using a pediatric probe (Vivid cardiovascular ultrasound 12S R-S, GE 
Healthcare Wordlwide), by counting the number of waveforms registered per minute. 
During each procedure, 20 measurements (30 seconds each) were obtained and averaged 
for each individual animal. In treated mice of main experiment, heart rate was measured 
before the beginning of treatment (baseline) and one week before sacrifice (9 and 21 days 
for the 2 weeks and 4 weeks treatment groups, respectively). Results were expressed as 
mean ± SEM. Differences between groups were analyzed by unpaired t-test and p<0.05 
was considered significant.  
 
3. Anesthesia  
 
All procedures that implied the sacrifice of mice were carried out by inducing a 
pharmacological coma with an overdose of Zoletil (100 mg/kg; Parnell Laboratories, 
Alexandria, NSW, Australia) and Dexdomitor (25 mg/kg; Zoetis, Florham Park, NJ, US). 
 
4. Cell culture 
 
Human umbilical vein endothelial cells (HUVECs) pools (Life Technologies, CA, US), 
were plated in gelatin-coated tissue culture dishes and maintained in phenol red-free basal 
medium M200 (Life Technologies, CA, US) containing 5% FBS and growth factors 
(LSGS, Life Technologies, CA, US) at 37°C with 5% CO2. Cells from passages 4 to 5 
were actively proliferating (70–90% confluent) when subjected to cone and plate system 
studies for 24 hours. 
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5. In vitro flow experiments 
 
To perform in vitro flow studies, a cone-and-plate flow apparatus was used. The cone is 
designed to fit into a 100-mm cell culture dish. The cone includes an upper lid that rests on 
the top of the dish to minimize the evaporation of the cell culture media. The lid also 
supports the free rotation of the cone on an axle secured by ball bearings and a setscrew, 
which controls the height of the cone from the cells plated in the cell culture dish. The cone 
is machined from a Teflon block to contain a 2.5-degree angle from its peak to its edge. 
Teflon does not typically bind proteins and additives from the media, and it does not 
interfere with cell viability. The cone can be smooth or grooved to mimic laminar or 
disturbed flows respectively. To rotate the cone, a magnetic stir bar is inserted into the 
cone that can be turned with a laboratory magnetic stirrer. The entire system (cone-and-
plate and magnetic stirrer) is assembled in an incubator at 37 °C with 5% CO2 (Figure 7). 
 
 
Figure 7: (A) Schematic representation of the cone and plate flow system. (B) Schematic representation of 
the contact surface area of a smooth cone. (C) Schematic representation of the contact surface area of a 
grooved cone. Image adapted from [80].  
 
HUVECs cultured in 100-mm dishes were exposed to S-flow at 50 dyn/cm
2
 (200 rpm) by 
using smooth cones or exposed to D-flow at 12.5 dyn/cm
2
 (50 rpm) by using grooved 
cones for 24 hours. The shear stress imposed on the surface of cells was calculated by the 
formula ωμ/θ where ω is the rotation speed, μ is the fluid viscosity, and θ is the angle of 
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the cone. After 24 hours, at least five random images were taken for each 100-mm dish 
using a phase contrast microscope with a 4X objective to monitor the cells status.  
 
6. Immunofluorescence on HUVEC cells 
 
HUVECs grown on 100-mm dishes were rinsed in ice cold PBS 1X, fixed in 4% PFA for 
15 min and rinsed twice in PBS 1X. HUVECs were permeabilized in PBS 1X + 0.2% 
Triton X-100 for 20 minutes and, after washing three times with PBS 1X, blocked in 
blocking buffer (10% NGS/PBS + 2.5% Tween-20) for 1 hour at room temperature. Cells 
were then incubated with the relative antibodies overnight at 4°C, previously prepared in 
the same blocking buffer. The primary antibodies used were Ve-Cadherin (1:250; BD 
Pharmingen), Notch1 (1:250; Millipore, MA, USA) and Notch4 (1:250; Millipore, MA, 
USA). 
After washing cells three times in PBS 1X, secondary antibodies, previously prepared in 
blocking buffer, were added and incubated for 1.5 hours rocking at dark and at 4°C. 
The secondary antibodies used were Alexa Flour 546 donkey Anti-Rabbit IgG (1:2000; 
Life Technologies, CA, US) and Alexa Flour 488 Goat Anti-Mouse IgG (1:500; Life 
Technologies, CA, US). After washing three times in PBS, ProLong Gold antifade (Life 
Technologies, CA, US) mounting medium was added and cells were covered with a 
coversplip. At least 5 images for a single staining were acquired on Zeiss LSM 510 
confocal microscope with 40x magnification. Results were expressed as mean ± SEM. 
Differences between groups were analyzed by unpaired t-test and p<0.05 was considered 
significant.  
 
7. RNA extraction from cells 
 
Total RNA was extracted using a commercially available kit (Qiagen, CA, USA). RNA 
concentration and purity were determined by Agilent 2100 Bioanalyzer (Agilent 
Technologies, CA, US). Protocol for RNA extraction is summarized below: 
  
1. Completely aspirate the cell-culture medium and disrupt the cells by adding 700µl of 
Buffer RLT to the cell-culture dish. Collect the lysate using a scraper. Pipet the lysate into 
a 2ml tube. Vortex or pipet to mix, and ensure that no cell clumps are visible before 
proceeding to step 2. 
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2. Pipet the lysate directly into a QIAshredder spin column placed in a 2ml collection tube, 
and centrifuge for 2 min at full speed. 
3. Add 1 volume (700µl) of 70% ethanol to the homogenized lysate, and mix well by 
pipetting. 
4. Transfer up to 700µl of the sample, including any precipitate that may have formed, to 
an RNeasy spin column placed in a 2 ml collection tube. Close the lid gently, and 
centrifuge for 15 s at 8000 x g (10,000 rpm). Discard the flow-through and reuse the 
collection tube in step 5.  
5. Add 700 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and centrifuge 
for 15 s at 8000 x g (10,000 rpm) to wash the spin column membrane. Discard the flow-
through and reuse the collection tube in step 6.  
6. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge 
for 15 s at 8000 x g (10,000 rpm) to wash the spin column membrane. Discard the flow-
through and reuse the collection tube in step 7. 
7. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge 
for 2 min at 8000 x g (10,000 rpm) to wash the spin column membrane. 
8. Place the RNeasy spin column in a new 2 ml collection tube (supplied), and discard the 
old collection tube with the flow-through. Close the lid gently, and centrifuge at full speed 
for 1 min. 
9. Place the RNeasy spin column in a new 1.5 ml collection tube. Leave the tube open 
under chemical hood for 5 min to remove all traces of ethanol. 
10. Add 30–50 μl RNase-free water directly to the spin column membrane. Close the lid 
gently, wait 3-5 min and centrifuge for 1 min at full speed to elute the RNA and the place 
the samples on ice.  
 
8. Endothelial enriched-RNA extraction 
 
After anesthesia, mice were placed in supine position and locked with needles. The 
peritoneum was opened and the thoracic cavity was completely cut, exposing heart and 
lungs. Then the left common iliac artery was cut to drain blood. To facilitate this 
procedure, a 26g needle was inserted into left ventricle and the heart was perfused, by 
gravity, with ice cold saline. When the effluent was completely clear, aorta was quickly 
and carefully isolated and placed into a Petri dish containing a RNAlater solution (RNA 
stabilization solution, Ambion). Under stereomicroscope (SMZ745T 6x-50x, Nikon, 
Chiyoda, Japan) the adventitial layer and fat portion of the aorta was cleaned off by 
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straining the aorta oppositely with angled forceps. Aortic arch was isolated cutting the 
aorta at the border of the thoracic portion. A microloader tip (Eppendorf - Germany) was 
adapted to an insulin syringe and filled with 300ul of Qiazol lysis solution (Qiagen, USA). 
 
Figure 8: Scheme of technique utilized for flushing mice aorta. (1) Brachiocephalic trunk (2) Left common 
carotid artery (3) Left subclavian artery.  
 
As shown in Figure 8, the microloader tip was carefully inserted in the aortic arch until it 
reached the left common artery, entering from the previously removed portion of thoracic 
aorta. Aortic arch was flushed with Qiazol lysis solution for 30 seconds and the eluate was 
collected into a RNase-free microfuge tube. As a control, RNA was isolated from other 
whole arch after mechanical disruption of the tissue using a Dounce homogenizer. In both 
cases, RNA was extracted using a commercially available kit (miRNeasy mini kit - 
Qiagen, CA, USA). RNA concentration and purity were determined by Agilent 2100 
Bioanalyzer (Agilent Technologies). Protocol for RNA extraction is summarized below:  
 
1. Add other 400ul of Qiazol lyisis buffer to the eluate 
2. Add 140 µl chloroform to the tube containing the homogenate and cap it securely. 
Shake the tube vigorously for 15 s. 
3. Place the tube containing the homogenate on the benchtop at room temperature for 
2–3 min. 
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4. Centrifuge for 15 min at 12,000 x g at 4°C. After centrifugation, heat the centrifuge 
up to room temperature (15–25°C) if the same centrifuge will be used for the next 
centrifugation steps. After centrifugation, the sample separates into 3 phases: an 
upper, colorless ,aqueous phase containing RNA; a white interphase; and a lower, 
red, organic phase. The volume of the aqueous phase should be approximately 
350µl.  
5. Transfer the upper aqueous phase to a new collection tube (supplied). Add 1.5 
volumes (usually 525 µl) of 100% ethanol and mix thoroughly by pipetting up and 
down several times. Do not centrifuge. 
6.  Pipet up to 700 µl of the sample, including any precipitate that may have formed, 
into an RNeasy Mini spin column in a 2 ml collection tube. Close the lid gently and 
centrifuge at ≥8000 x g (10,000 rpm) for 15 s at room temperature (15–25°C). 
Discard the flow-through. 
7.  Repeat step 6 using the remainder of the sample. Discard the flow-through.* 
8. Pipet 500 µl Buffer RPE onto the RNeasy Mini spin column. Close the lid gently 
and centrifuge for 15 s at 8000 x g (10,000 rpm) to wash the column. Discard the 
flow-through. 
9. Add another 500 µl Buffer RPE to the RNeasy Mini spin column. Close the lid 
gently and centrifuge for 2 min at 8000 x g (10,000 rpm) to dry the RNeasy Mini 
spin column membrane. 
10. Transfer the RNeasy Mini spin column to a new 1.5 ml collection tube (supplied). 
Pipet 30–50 µl RNase-free water directly onto the RNeasy Mini spin column 
membrane. Close the lid gently and centrifuge for 1 min at 8000 x g (10,000 rpm) 
to elute the RNA. 
 
9. Reverse Transcription and Real Time PCR 
 
500 ng of total RNA (from cells) or 140ng of total RNA (pool from 2 aortas) were reverse 
transcribed in a volume of 25 ml using 250 units of SuperScript III reverse transcriptase 
and 50 ng of random hexamers. Here briefly report the protocol: 
 
1. Mix and briefly centrifuge each component before use. 
2. Combine the following components in a 0.2- or 0.5-ml RNAse free tube: 
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Random Primer (50ng/ul) RNA (500ng) dNTPs DEPC- water TOTAL 
2,5 μl 4 μl 1,25 μl 8,5 μl 16,25 μl 
 
3. Incubate at 65°C for 5 min, then place on ice for at least 1 min.  
4. Prepare the following cDNA Synthesis Mix: 
 
5x First Strand Buffer 0,1M DTT Rnase OUT SuperScript III RT TOTAL 
5 μl 1,25 μl 1,25 μl 1,25 μl 8,75 μl 
 
5. Add 8.75 μl of cDNA Synthesis Mix to each RNA/primer mixture, mix gently, and 
collect by brief centrifugation. Incubate as follows. 
 10 min at 25°C 
 50 min at 55°C 
 15 min at 85°C  chill on ice. 
 
2 µl of the cDNA mixture were used for realtime PCR experiments. Real-time PCR 
reactions were conducted on an Applied Biosystems 7500 Fast Real-Time PCR System 
using PerfeCta SYBR Green SuperMix with ROX kit (Quanta Biosciences, MD, US) 
according to the manufacturer’s protocol in a final volume of 25 µl. Primers concentration 
was 500 nM. The following primers were used:  
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Changes in gene expression were calculated by the 2
−ΔΔCt
 formula using RPL13A as 
reference gene. Results were expressed as mean ± SEM. Differences between groups were 
analyzed by unpaired t-test and p<0.05 was considered significant.  
 
10. Microarray Analysis  
 
Time course experiment: Sixteen ApoE -/- mice (5 weeks old) were received and let 
acclimate for one week in our animal facility before extracting RNA from the first group (6 
weeks old). RNA from 6-, 7-, 8- and 10-weeks old ApoE -/- mice was isolated by flushing 
the aortic arch and was purified using the miRNeasy mini kit, as previously described. 
70ng of RNA from 2 mice in each age group of age, analyzed in duplicate, were pooled to 
obtain a final amount of 140ng. RNA from 8 samples was hybridized on a slide containing 
8 slots as described in the following table: 
 
ApoE-/- mice (n=4/group) Microarray Chip 
6 weeks old ApoE 1 + ApoE 2 ApoE 3 + ApoE 4 
7 weeks old ApoE 5 + ApoE 6 ApoE 7 + ApoE 8 
8 weeks old ApoE 9 + ApoE 10 ApoE 11 + ApoE 12 
10 weeks old ApoE 13 + ApoE 14 ApoE 15 + ApoE 16 
 
 
Main experiment: Eighteen 5 weeks old ApoE -/- mice were received and let acclimate 
for a week in our animal facility before beginning treatment (30 mg/kg/day in drinking 
water ad libitum – 2 o 4 weeks treatment). At the end of the treatment, a microarrays 
analysis was conducted to characterize changes in the gene expression profile in 
endothelial cell-enriched RNA purified from aortas of 8 and 10 weeks old ApoE-/- mice, 
following 2 weeks and 4 weeks ivabradine treatment respectively. RNA quality and yield 
was determined by Agilent 2100 Bioanalyzer (Agilent Technologies). 
70ng of RNA from 2 mice in each treated group were pooled to obtain a final amount of 
140 ng (each treated age group was analyzed in triplicate – n=6 per group). The remain 
RNAs (3 samples at 8 weeks and 3 samples at 10 weeks) were kept aside for qRT-PCR 
analysis. Moreover we analyzed gene expression in RNA from 8 weeks (n=2) and 10 
weeks old (n=2) ApoE-/- mice, which did not received treatment, to obtained a triplicate 
analysis for untreated mice by including data from the time course experiment. 
All the RNAs are described in the following table: 
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Microarray Chip 
ApoE 1 + ApoE 2 (8 weeks untreated) ApoE 3 + ApoE 4 (10 weeks untreated) 
ApoE 5 + ApoE 6 (8 weeks treated) ApoE 11 + ApoE 12 (10 weeks treated) 
ApoE 7 + ApoE 8 (8 weeks treated) ApoE 13 + ApoE 14 (10 weeks treated) 
ApoE 9 + ApoE 10 (8 weeks treated) ApoE 15 + ApoE 16 (10 weeks treated) 
 
For both experiments, all samples were hybridized on Agilent Whole Mouse Gene 
Expression Microarray (#G4122F, Agilent Technologies, Palo Alto, CA) and one-color 
gene expression was performed according to the manufacturer’s procedure. Labeled cRNA 
was synthesized from total RNA using the Low RNA Input Linear Amplification Kit 
(Agilent Technologies) in the presence of cyanine 3-CTP (Perkin-Elmer Life Sciences, 
Boston, MA). Hybridizations were performed at 65°C for 17 hours in a rotating oven. 
Images at 5μm resolution were generated by Agilent scanner and the Feature Extraction 
10.5 software (Agilent Technologies) was used to obtain the microarray raw data. 
Microarray results were analyzed by using the GeneSpring GX 11 software (Agilent 
Technologies). Data transformation was applied to set all the negative raw values at 1.0, 
followed by a quantile normalization. A filter on low gene expression was used to keep 
only the probes expressed in at least one sample (flagged as Marginal or Present). 
Differentially expressed genes were selected as having a ≥ 1.5-fold or ≥ 2-fold expression 
difference between the groups of interest and a p-value ≤ 0.05 or 0.01 at unpaired t test.  
Hierarchical clustering was performed using Manhattan correlation as a measure of 
similarity. To identify underlying biological pathways the differentially expressed genes 
were then analyzed using MetaCore™ (GeneGo, Inc., St. Joseph, MI, USA) or DAVID 
Bioinformatics Resources 6.7 (National Institute of Allergy and Infectious Diseases 
NIAID, NIH), web-based computational platforms designed for systems biology. 
 
11. En-face Analysis  
 
Mice were euthanized and orta was perfused with saline solution and fixed for 10 minutes 
with 4% paraformaldehyde. Aorta was excised, cleaned of fat and fibrous material in a 
Petri dish containing ice cold saline solution.  
Segments of thoracic aorta and aortic arch were isolated. From the aortic arches we 
identified and excised the areas corresponding to both lesser and major curvatures 
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(described in [81]). Staining procedure was performed in 2 ml tube filled with enough 
buffers to cover the tissue. Aorta segments were blocked with 1 ml of blocking buffer 
(PBS 1X + 0.1% Triton X-100 +2% BSA) rocking at room temperature for 1.5 hours. 
Primary antibody incubations were performed overnight at 4°C. The primary antibodies 
used were Ve-Cadherin (1:100; BD Pharmingen), Hey2 (1:100; Millipore), Hes5 (1:100; 
Santa Cruz Biotechnology, Germany), Notch1 (1:100; Santa Cruz Biotechnology, 
Germany) and Notch4 (1:100; Santa Cruz Biotechnology, Germany). After washing the 
aortic segments three times in washing buffer (PBS 1X + 0.1% Triton X-100), secondary 
antibodies, previously prepared in blocking buffer, were added and incubated for 1.5 hours 
rocking at dark and at 4°C. The secondary antibodies used were Alexa Flour 546 Goat 
Anti-Rat IgG (1:500; Life Technologies, CA, US), Alexa Flour 633 Goat Anti-Rabbit IgG 
(1:500; Life Technologies, CA, US). After washing three times, aortic specimens were 
placed on a glass slide with the intima side up and, before covering samples with a 
coverslip, a drop of a liquid mountant was applied directly to fluorescently labeled tissue 
samples (ProLong Antifade Reagents – Life Technologies, CA, US). At least 5 images of 
the endothelial monolayer were obtained using a Zeiss LSM 510 confocal microscope with 
40x magnification. Results were expressed as mean ± SEM. Differences between groups 
were analyzed by unpaired t-test and p<0.05 was considered significant.  
 
12. Immunofluorescence on frozen section of aorta 
 
Mice were euthanized and aorta was perfused with saline solution to flush blood inside the 
aorta itself. The portion of aorta corresponding to the aortic arch was isolated and snap-
frozen in blocks of OCT gel. Longitudinal sections (10 µm thick) were placed on 
Superfrost Ultra Plus adhesion slides (Thermo Scientific- Waltham, MA, US) (3 sections 
per slide) and left dry for 2 hours at room temperature. Slides were fixed in ice-cold 
acetone for 15 min and left dry under chemical wood for 30 minutes. The surplus of OCT 
was discarded, using a scalpel, and a circle was drawn around every section, using a 
PAPpen (Ab2601 - Abcam - UK), to perform staining procedure. Slides were submerged 
in blocking buffer (PBS 1X + 0.1% Triton X-100 +2% BSA) for 1.5 hours. 
Primary antibody incubations were performed overnight at 4°C. The primary antibodies 
(prepared in blocking buffer) used were Ve-Cadherin (1:100; BD Pharmingen) and Hes5 
(1:100; Santa Cruz Biotechnology). After washing the aortic segments three times in PBS 
1X, secondary antibodies, previously prepared in blocking buffer, were added and 
incubated for 1.5 hours rocking in the dark, at 4°C. 
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The secondary antibodies used were Alexa Flour 546 Goat Anti-Rat IgG (1:500; Life 
Technologies, CA, US) and Alexa Flour 633 Goat Anti-Rabbit IgG (1:500; Life 
Technologies, CA, US). After washing three times in PBS 1X, a drop of a liquid mountant 
(ProLong Antifade Reagents - Life Technologies, CA, US) was applied directly to 
fluorescently labeled tissue samples and covered with a coverslip. Images of the 
endothelial monolayer were obtained using a Zeiss LSM 510 confocal microscope with 
40x magnification. At least 10 images were acquired for a single staining. 
Image analysis was performed using ImageJ, an open source bioimaging software. Red 
signal, corresponding to VE-cadherin staining, was binarized and used as a mask image to 
select positive signal in correspondence of endothelium. Such a mask image was used to 
filter the raw signals for Hes5 (green channel) and to select the region of interest (ROI) 
where it co-localized with red signals. The average fluorescence intensities were calculated 
for each sample as described in [82]. The data obtained with this approach were compared 
with data obtained by manually conducted analyses. Specifically, a ROI corresponding to 
the endothelium (VE-cadherin staining), was manually selected within a box. The ROIs 
selected for each VE-cadherin staining were placed into the same images for HES5 
staining (green channel) and the ratio pixel signal intensity levels for each ROI were 
recorded (described in [83]). Results were expressed as mean ± SEM. Differences between 
groups were analyzed by unpaired t-test and p<0.05 was considered significant.  
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3) RESULTS AND DISCUSSION 
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1.  Validation of endothelial cells enriched-RNA extraction 
 
In order to increase the specificity of microarrays we attempted to isolate RNA from 
endothelium only, using the method described by Krenek P et al., [84]. Aortic arch of five 
10 weeks old C57BL6/J mice were flushed with different volumes of a phenol containing 
solution to achieve efficient lysis of endothelial cells only: more than 350 µlof Qiazol lysis 
buffer caused a disgregation of the whole arch, conversely smaller volume of lysis buffer 
resulted in insufficient RNA yield (data not shown). Noteworthy, to obtain an efficient 
RNA extraction and to avoid aorta dissolution, it was needed to constantly perfuse the 
aorta for not more than thirty seconds. As expected, this method gave a low yield of RNA 
(150-600ng from one arch, n=5 10 weeks old C57BL6/J ) nevertheless every target gene 
was successfully amplified by qRT-PCR (Figure 9A). RNA was also isolated from the 
whole arch after mechanical disruption of the tissue using a Dounce homogenizer and the 
same lysis buffer used for flushing the aorta. This method gave good yield and good 
quality RNA (1.5 ug total RNA from one arch). Successful endothelial enriched-RNA 
extraction was confirmed by measuring mRNA levels of endothelial and smooth muscle 
specific genes (eNOS and SM22 respectively). As shown in Figure 9B, RNA extracted 
from endothelium only was enriched with eNOS and depleted of SM22 compared to RNA 
purified from whole aorta. 
 
  
 
Figure 9: (A) Fluorescence amplification curves of tested genes; (B) Enrichment of endothelial specific 
markers in RNA extracted by the flushing technique: difference in eNOS and SM22 mRNA levels is shown 
by difference of relative Ct numbers (W-AORTA= RNA from whole aortic arch, E-AORTA:RNA from 
endothelium only). 
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2. PRELIMINARY EXPERIMENTS: Time course experiment and ivabradine 
treatment dose 
 
The aim of these experiments was to establish i) the age to start the ivabradine treatment 
and the duration of treatment ii) the dose of ivabradine. 
 
2.1 Time course experiment: microarray analysis in endothelial cell transcripts-
enriched RNA purified from aortas of 6, 7, 8 and 10 weeks old ApoE-/- mice 
 
To assess the age of the onset of changes in gene expression in the endothelium of 
ascending aorta and, thus, to determine the beginning and duration of ivabradine treatment, 
we compared the gene expression profile in 6, 7, 8 and 10 weeks old ApoE-/- mice. The 
time point of 6 weeks-old was chosen for ivabradine treatment start because it corresponds 
to the early stage of atherosclerosis development in chow-fed ApoE-/- mice (i.e. before 
start of monocyte adhesion) [85]. Whereas it has been reported that in ApoE-/- mice fed a 
normal diet, signs of atherosclerosis progression (monocyte adhesion, foam cell lesion) are 
present at 10 weeks of age [85], there are not many data available on changes in gene 
expression in the endothelium of aortic arch of younger mice fed the same diet. Therefore, 
we included in our analyses a group of mice to be sacrificed at 10 weeks of age as positive 
control for atherosclerosis progression and as validation of methodologies utilized for our 
study.  
The overall quality of the expression chip was examined and all quality assessment 
variables were within the acceptance limits suggested by the manufacturer. In order to 
verify , in agreement with the literature, if we could detect under our experimental 
conditions changes in expression of atherosclerosis-associated genes at 10 weeks, we 
analyzed differences in gene expression between 6 weeks and 10 weeks (Figure 10 – left 
panel). The total number of genes significantly modulated between these two time points 
was 1080 (fold change cut-off: 2.0). Among these genes, 308 were down-regulated and 92 
were up-regulated more than 4-fold. These same genes showed instead variable expression 
in 7 and 8 weeks old mice (Figure 10 – right panel ). We detected changes in 137 
uncharacterized expressed sequence tags (ESTs), 102 Riken cDNA sequences (sequences 
with open reading frames coding for unknown proteins) and 202 long intergenic non-
coding RNAs (lincRNA) 
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Figure 10: Left: Heatmap of gene expression hierarchical clustering comparing samples at 6 weeks versus 
10 weeks. The represented genes were sorted out filtering values that were significantly differentially 
expressed between 6 and 10 weeks. Each column of data represents 1 of the 2 replicate experiments (pool of 
2 aortas). Right: Heatmap of gene expression hierarchical clustering comparing samples at 6 weeks versus 10 
weeks including expression levels of the same genes at 7 and 8 weeks. 
 
The analysis of the affected pathways (MetaCore analysis) identified pathways involved in 
modulation of cell cycle, cell adhesion, immune response, atherosclerosis and apoptosis. 
We found downregulation of cyclin B1, cdk1, and survivin (an inhibitor of caspase 9) 
(Figure 11), which suggests apoptosis following G2/M cell cycle arrest [86,87]. Increased 
apoptosis was suggested also by up-regulation of Phap1, a stimulator of mitochondrial 
apoptotic pathway. We found significant differences in the expression of genes for 
chemokine receptors and their ligands (Ccl3, Ccr7, Ccr9, Ccrl1), for interleukins and their 
receptors (Il10ra, Il17rb, Il18bp, Il5ra, Il7r) and for the matrix metallopeptidase 9 (Mmp9).  
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Figure 11: GeneGo pathway analysis. Down-regulation of cyclin B1, cdk1, and survivin (highlighted by red 
circles) is indicated by blue thermometer. 
 
Since microarray data showing significant changes (above 2-fold) derived from low signal 
intensities maybe biased or masked by noise whereas a 1.4-fold change derived from 
strong signal intensities may reflect actual changes in mRNA concentration within a 
biological sample [88], we also checked genes giving a strong hybridization signal that 
showed changes progressing with time even if they not always reached statistical 
significance. Using this approach we identified additional chemokine receptors and their 
ligands (Ccl17, Ccl4, Cxcl17, Ccr6, Ccr9, Cxcr2, Cxcr5), interleukins and their receptors 
(Il1b, Il10ra, Il17rb, Il18bp, Il20rb, Il25) and cadherins 16 and 18. Of interest, since 
calcium signalling pathway is known to be involved in the inflammatory process of 
atheroscleros [89] and Clca1 has been shown to regulate endothelial cell permeability [90], 
we found a strong down-regulation of Clca3 (chloride channel calcium activated 3 gene, 
down-regulated 29-fold). Rag1 and Rag2 (recombination activating gene 1 and 2), 
involved in modulation of inflammation by controlling maturation of T and B cells [91] 
were downregulated 19.1- and 10.5-fold respectively and Mmp12 (matrix metalloproteases 
12), associated to initiation of atherosclerosis [92], was up-regulated 3-fold.  
We found upregulation of SerpinA3i (serine (or cysteine) peptidase inhibitor, clade 
A,member 3I) which belongs to family of protease inhibitors and is highly expressed in 
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ApoE-/- mice lesions compared with lesion-free vessels [93]. Moroever, Serpina3k (serine 
(or cysteine) peptidase inhibitor, clade A, member 3K), which protects retinal cells from 
oxidative stress-induced cell death [94], was downregulated 16-fold. We didn’t detect 
changes in expression of ICAMs, VCAMs and MCP-1 at 10 weeks. Among the other 
modulated genes we identified: ATP-binding cassette, sub-family B (MDR/TAP), member 
1A (Abcb1a), synaptogyrin 1 (syngr1) , complement component 1- q subcomponent- alpha 
polypeptide (C1qa), ring finger protein 149 (rnf149) , lipocalin 2 (Lcn2), interleukin 7 and 
10 receptors (Il7r e Il10ra), RIKEN cDNA 5430435G22 gene (5430435G22Rik), Harvey 
rat sarcoma virus oncogene (Hras1), hepatocyte growth factor (Hgf), extra cellular 
proteinase inhibitor (Expi), ATP-binding cassette, sub-family C, member 3 (Abcc3). All 
these genes were previously identified by Tabibiazar and colleagues as associated to 
progression of atherosclerosis in ApoE-/- mice [95]. Interleukin 1 b (Il1b) was up-regulated 
(2.27-fold) as observed in endothelial cells Weibel-Palade bodies following an 
inflammatory stimulus [96]. This overlapping with published data is a validation of our 
methodology and analysis algorithm. 
 
 A statistical analysis of changes of gene expression at 7 weeks compared to 6 weeks 
(Figure 12, left) identified 603 genes (fold change cut-off: 2). Among these genes, 105 
were up- or down-regulated more than 4-fold. We indentified changes in 34 
uncharacterized  ESTs, 50 Riken cDNA sequences and 169 lincRNA. Among the affected 
pathways we identified pathways related to immune response (including 2 pathways 
associated to oncostatin M involved in atherosclerosis progression [95]), atherosclerosis 
and cell adhesion. Of interest among these genes, we identified up-regulation of a 
chemokine receptor (Ccrl1) and ligands (Ccl11, Ccl12) and down-regulation of cadherin 1 
(cdh1). Ccl2 (MCP-1) was up-regulated but not ICAM and VCAM. Svep1 (coding for a 
protein that includes complement binding motifs, von Willebrand factor (vWF-A) type A 
domain, Epidermal Growth Factor (EGF) and EGF-like calcium binding and pentraxin 
domains) involved in the regulation of expression of ICAM1 and E-selectin [97] was up-
regulated 2.2-fold. 
 
A statistical analysis of changes in gene expression at 8 weeks compared to 6 weeks 
(Figure 12, right) showed 538 genes affected (fold change cut-off: 2). 84 genes were up- or 
down-regulated more than 4-fold. We found changes in 118 lincRNA, 20 uncharacterized 
ESTs and 64 Riken cDNA sequences. Among the pathways identified there were some 
related to immune response, atherosclerosis, cell adhesion and apoptosis. Of interest 
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among the modulated genes we identified up-regulation (Ccl8, Ccrl1) and down-regulation 
(Ccr7) of chemokine receptors and ligands. We found upregulation of Ccl2 (MCP-1) but 
we didn’t detect changes in ICAMs and VCAMs genes at 8 weeks.  
 
 
 
Figure 12: Heatmap of gene expression hierarchical clustering comparing samples at 6 versus 7 weeks (left 
panel) and 6 versus 8 weeks (right panel). The represented genes were sorted out filtering values that were 
significantly differentially expressed at 6 weeks versus 7 and 8 weeks. 
 
As shown in Figure 13, many of the genes affected at  7 weeks followed a similar trend at 
8 weeks (398 genes) (Figure 13, left) and maintained the same expression level at 10 
weeks (Figure 13, right). 40 genes in this group were up- or down-regulated more than 4-
fold. Among them there were chemokine receptors and ligands (Ccl8, Ccrl1, Ccr10, Ccr7). 
Of interest, a transcript containing sequences for von Willebrand factor A domain 
containing 3B (Vwa3b-003) was up-regulated at 7, 8 and 10 weeks. We also found up-
regulation of platelet-activating factor receptor (Ptafr) , which has been shown to dissociate 
endothelial cells adherens junctions [98]. 
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Figure 13: Left: Heatmap of gene expression hierarchical clustering comparing samples at 6 weeks versus 7 
plus 8 weeks showing gene expression. The represented genes were sorted out filtering values that were 
significantly differentially expressed between 6 weeks versus 7 plus 8 weeks. Right: Graphic representation 
of genes significantly differentially expressed at 7 and 8 weeks and their expression level at 10 weeks. 
 
In conclusion, we found changes in the expression of a significant number of genes and in 
particular genes related to inflammation as early as at 7 weeks of age. Some of the 
modulated genes followed the same trend at 8 and 10 weeks. The number of affected genes 
increased with time, therefore the highest variation in terms of gene number and degree of 
changes was seen at 10 weeks. Based on these results we conclude that either one or two 
weeks of ivabradine treatment beginning at 6 weeks of age could be chosen to study the 
effect of the drug on gene expression. Furthermore, based on the observation that at 10 
weeks there is the highest number of affected genes, we reasoned that the inclusion of an 
additional 10 weeks time point (4 weeks of ivabradine treatment) could increase our 
chances to detect an effect of ivabradine on gene expression. 
 
2.2 Heart rate reduction induced by ivabradine treatment 
 
Preliminary experiments were conducted to determine the ivabradine treatment dose. 6 
weeks old ApoE-/- mice (n=5) were treated with ivabradine for 6 days. The dose of 15 
mg/kg/day was first chosen, since, as shown by Custodis and colleagues, 10 mg/kg/day of 
ivabradine treatment induce a reduction of 13% ± 2 and 20 mg/kg/day lead to a reduction 
of ~ 23% [99,100]. At the end of 6 days treatment HR was monitored and as indicated in 
Figure 14 we observed a mean HR of 639 BPM (beat per minutes) ± 8 after treatment 
compared to mean HR of 714 BPM ± 15 measured before treatment (baseline), with an 
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average percent reduction of heart rate (% HRR) of 10,5 % ± 2,6. The HR reduction 
obtained was slightly below to that found by Custodis et al with 10 mg/kg/day of 
ivabradine (~ 13%).  
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Figure 14: Mean HR (BPM) in ApoE -/- mice before and after ivabradine treatment. 
** 
p value< 0,005 
 
We used a higher dose of ivabradine (30 mg/Kg/day) to obtain a more sustained heart rate 
reduction.  
As indicated in Table 1 and Figure 15, we observed an % HRR of 10,2 ± 5,6 at day 3. If 
we exclude one mouse (APO 5) in which there was no HR reduction (probably due to 
reduced water assumption) the % HRR was 12,2 ± 3,7. Treatment was continued for the 
following 3 days and led to a higher % HRR (17,8 ± 4,7).  
 
 
BASELINE 
(BPM) 
HR (BPM) 
IVA DAY 3 
HRR % 
HR (BPM) 
IVA DAY 6 
HRR % 
APO 1 737,9 679 7,98% 644,4 12,67% 
APO 2 768,9 679,8 11,59% 658,5 14,36% 
APO 3 763,2 669,6 12,26% 635,3 16,76% 
APO 4 771,8 641,5 16,90% 603,7 21,78% 
APO 5 742,6 724,2 2,47% 580,5 23,66% 
AVERAGE 
APO 1-5 
756,9 678,82 10,24% ± 0,054 624,48 17,85% ± 0,047 
AVAREGE 
APO 1-4 
- 667,48 12,18% ± 0,037 - - 
 
Table 1: Heart rate measurement in Apo E -/- before and after ivabradine treatment. Measurement at day 3 
and day 6. 
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Figure 15: Percent heart rate reduction (% HRR) in Apo E -/- mice after ivabradine treatment (dose and time 
as indicated in the figure). 
 
These results indicate that 6 days treatment with 15mg/Kg/day of ivabradine is adequate to 
induce an average reduction of heart rate of ~ 12% and that the highest dose of ivabradine 
(30 mg/Kg/day) is necessary if a more substantial heart rate reduction is desirable. 
 
3. MAIN EXPERIMENT: Ivabradine treatment in ApoE -/- mice 
 
Based on the data obtained by preliminary experiments, the higher dose was chosen for the 
“main experiment” (30mg/kg/day in drinking water). Since both a longer exposure to 
ivabradine seemed to give a more reproducible effect on heart rate reduction, and many of 
the genes affected at 7 weeks followed a similar trend at 8 weeks (time course microarray), 
we chose to measure gene expression at 8 weeks, instead of 7 weeks (following two weeks 
treatment with ivabradine). We included an additional time point (4 weeks of ivabradine 
treatment) since, as previously reported in preliminary experiment, in 10 weeks old ApoE -
/- mice we found the highest number of modulated genes. A 10 weeks time point can still 
be considered “early stage” in atherosclerosis progression since published data [95] have 
shown that gene expression profile in aortas of 10 weeks old ApoE -/- mice is more similar 
to the gene expression profile of younger and healthy mice than to the gene expression 
profile of 30 and 40 weeks old mice which show clear signs of advanced atherosclerosis. 
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3.1  Microarray analysis in endothelial cell transcripts-enriched RNA purified from 
aortas of 8 and 10 weeks old ApoE-/- mice following treatment with ivabradine 
 
In treated mice, heart rate was measured before the beginning of treatment (baseline) and 
one week before sacrifice (day 9 and 21) (Figure 16). At day 0 (baseline) we observed a 
mean HR of 726 BPM ± 8. At day 9, we found a mean HR of 600 BPM ± 9, with a 
corresponding HRR % of 17,4 ± 1,7. At day 21, we found a mean HR of 560 BPM ± 12, 
with a corresponding HRR % of 22,9 ± 2,1.  
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Figure 16: Mean HR (BPM) in ApoE -/- mice before and after ivabradine treatment. 
*** 
p value < 0,0001 
  
At the end of the treatment, a microarrays analysis was conducted to characterize changes 
in the gene expression profile in endothelial cell-enriched RNA purified from aortas of 8 
and 10 weeks old ApoE-/- mice, following 2 weeks and 4 weeks ivabradine treatment 
respectively (analysis performed in triplicate). 
As described in “method”, to obtain a triplicate analysis for untreated mice, in this 
microarray chip, it was analyzed RNAs from untreated 8 weeks- (n=2) and 10 weeks-old 
(n=2) ApoE-/- mice, which gene expression results were merged with data obtained from 8 
weeks and 10 weeks old untreated mice from the time course experiment.  
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3.2 Identification of differentially expressed genes 
 
List 1 – differentially gene expression in ApoE-/- at 8 weeks and 10 weeks after 
ivabradine treatment  
 
We first analyzed separately the two groups of mice at different ages (8 and 10 weeks old) 
and compared changes in gene expression in untreated versus treated group (2 weeks or 4 
weeks of ivabradine treatment). 
Hierarchical clustering showed that the number of sequences significantly modulated (p-
value cut-off: 0.01, fold change ≥ 2.0) after 2 weeks of treatment was 146 (80 upregulated 
and 66 downregulated) (Figure 17). Among the modulated sequences we found 17 
uncharacterized ESTs, 14 Riken cDNA sequences and 52 lincRNAs. After 4 weeks of 
treatment, the number of sequences significantly modulated (p-value cut-off: 0.01, fold 
change ≥ 2.0) was 278 (127 upregulated and 151 downregulated) (Figure 17). Among them 
we found 17 uncharacterized ESTs, 12 Riken cDNA sequences and 78 lincRNAs. 
 
Figure 17: Heatmap of hierarchical clustering of gene expression in samples from 8 weeks old mice     
(untreated or ivabradine-treated) (left panel) and 10 weeks old mice (untreated or ivabradine-treated) (right 
panel). Each column represents expression data from 1 of 3 pools of aorta (each pool from 2 mice). 
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Eleven sequences were similarly modulated in both treatment groups (Table 2) Among the 
modulated sequences (8 upregulated and 3 downregulated) 4 sequences were long 
intergenic non-coding RNAs (lincRNA) and one sequence was a Riken cDNA. We found 
upregulation of paired box gene 2 (Pax2 – 2.16-fold), with anti-apoptotic function in renal 
collecting duct cells [101] and of zinc finger protein 407 gene (Zfp407 – 2-fold), key 
stimulator of Glucose Uptake and Glucose Transporter 4 (GLUT4), which impairment 
underlined hyperglycemia and increased risk of cardiovascular disease and neuropathy 
[102].  
We found downregulation of T-cell leukemia, homeobox 2 gene (Tlx2 – 9.5-fold) which is 
induced by the BMP2 (bone morphogenetic protein)/SMAD pathway [103] which is 
activated by AngII in HUVECs and signals through NF-κB [104]. Among downregulated 
sequences, we found Lass3 (LAG1 homolog ceramide synthase 3 – 3.14-fold), involved  in 
the synthesis of ceramide species, including C18:0- and C24:0-ceramides [105], that are 
elevated in subjects’ plasma with type 2 diabete [106]. 
 
 
Table 2: Overlapping genes modulated by ivabradine treatment at 8 weeks and 10 weeks.  
 
 
 
 
 
 
Gene name 
FC(abs) (Moderated  T-
Test [10-T] Vs [10-NT])
p-value Regulation
FC(abs) (Moderated  T-
Test [8-T] Vs [8-NT])
p-value Regulation
lincRNA:chr19:54011403-
54018978 forward strand
2,1 0,0060 up 3,2 0,0040 up
 T-cell leukemia, homeobox 2 
(Tlx2)
5,3 0,0047 down 9,5 0,0098 down
 paired box gene 2 (Pax2) 2,8 0,0018 up 2,2 0,0059 up
 zinc finger protein 407 (Zfp407) 2,6 0,0045 up 2,0 0,0005 up
603396379F1 NIH_MGC_94  cDNA 
clone IMAGE:5400378 5', mRNA 
sequence [BI872080]
2,2 0,0090 up 3,9 0,0055 up
lincRNA:chr7:69117827-69127242 
reverse strand
3,4 0,0003 up 3,4 0,0051 up
lincRNA:chr9:56912321-56912932 
reverse strand
3,7 0,0020 up 3,3 0,0026 up
LAG1 homolog, ceramide synthase 
3 (Lass3)
2,1 0,0084 down 3,1 0,0016 down
lincRNA:chr5:121765763-
121768660 forward strand
2,2 0,0020 up 2,3 0,0084 up
PDZ domain containing 1 (Pdzk1) 6,1 0,0059 down 4,5 0,0057 down
glutamate receptor, ionotropic, 
kainate 4 (Grik4)
2,3 0,0075 up 2,8 0,0062 up
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LIST 2 – Comparison of gene expression profile between Treated and  Untreated 
ApoE-/- mice 
 
Three components PCA was carried out to determine whether the observed variability in 
gene expression could be attributed to ivabradine treatment or rather to mice age (mice 
were 8 and 10 weeks old at the end of the treatments). The results of this analysis are 
shown in Figure 18. In the graphic representation of the PCA are visible two clearly 
separated groups corresponding to treated and untreated individuals (blue vs red). The 
different ages in each group (triangles vs diamonds and circles vs squares) are randomly 
distributed in the 3D space. These results indicate that most of the variability in gene 
expression between the groups is ivabrabine- and not age- related and they provide the 
rational for generating a list which includes genes differentially expressed between treated 
and untreated groups. 
 
Figure 18: Unsupervised principal components analysis (36K expressed genes). In blue circle all the treated 
groups. In red circle all the untreated groups 
 
Based on this result, we compared the gene expression data relative to untreated (8 and 10 
weeks old) and treated mice (8 and 10 weeks old after 2 and 4 weeks treatment 
respectively).The heatmap indicating the clustering of treated and untreated groups is 
shown in Figure 19. The total number of sequences significantly modulated (p-value cut-
off: 0.01, fold change ≥ 1.5) was 930 (630 upregulated and 300 dowregulated). Among the 
modulated sequences we found 73 uncharacterized ESTs, 61 Riken cDNA sequences and 
314 lincRNAs.  
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Figure 19: Heatmap of hierarchical clustering of gene expression in samples from untreated and ivabradine- 
treated (each group contains 8 and 10 weeks old mice ). Each column represents expression data from 1 of 3 
pools of aorta (each pool from 2 mice). 
 
In order to ensure that the observed differences between the two groups were not due to the 
different levels of VSMCs RNA among the groups, clustering analyses were performed for 
selected VSMC-specific genes (Acta2,Taglin,Cnn1). Treated and untreated groups were 
randomly distributed when the specific VSMC transcripts were taken in consideration 
(Figure 20).  
 
Figure 20: Heatmap showing hierarchical clustering of expression of Acta2, Tagln and Cnn1 in samples 
from 8 and 10 weeks old mice treated or not with ivabradine. The random distribution of treated and 
untreated groups is highlighted in red box. (T: treated; NT: untreated) 
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Additionally, correlation analyses showed that whereas the expression levels of transcripts 
(Rasgrf2 and PRKCA) modulated by ivabradine treatment showed high levels of 
correlation, with a separate distribution of untreated and treated groups (Figure 21) 
 
 
Figure 21: Correlation analysis between expression levels of ivabradine modulated genes (Rasgrf2 and 
PRKCA) 
 
and, similarly, VSMC specific transcripts were highly correlated with random distribution 
of treated and untreated groups (Figure 22), 
 
 
Figure 22: Correlation analysis between expression levels of VSMCs transcripts (Tagln and Cnn1) 
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there was no correlation between the expression levels of transcripts and VSMc specific 
transcripts (Figure 23). 
 
 
Figure 23: Correlation analysis between expression levels of ivabradine modulated gene (Rags) and a 
vascular smooth muscle cell transcript (Cnn1) 
 
3.3 Analyses of individual genes 
 
To identify potentially interesting genes on which to focus our analyses, we performed an 
automated literature search on PubMed for association between genes in List 2 and the 
terms “atherosclerosis” or “inflammation” or “shear stress” in published papers. These 
analyses brought to the identification of several genes involved in the first steps of 
atherosclerosis onset and progression, such as genes related to:  
 
- Endothelial cells integrity and permeability: 
 
o Nppc (Natriuretic peptide type C - dowregulated 5.7-fold): atrial natriuretic peptide 
(ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) are 
all involved in the maintenance of electrolyte-fluid balance and vascular tone [107]. 
Many studies have shown that CNP is produced endogenously by the endothelium 
in response to blood vessels injury and it is thought to be involved in its repair. 
CNP is secreted by endothelium under the action of pro-inflammatory cytokines 
[108]. CNP expression is upregulated in human coronary atherosclerotic lesions of 
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asymptomatic patients [109], in serum of elderly patients carrying CAD [110] and 
patients with rheumatoid arthritis [111]. It is increased in urine of acute 
decompensated heart failure patients[112]. Clinical and functional improvement 
after physical training in heart failure patients is associated with a decrease in CNP 
concentration, which has been speculated might reflect an improvement in 
endothelial function [113]. Nppc is regulated by shear stress in HUVECs [114,115]. 
(Nppc expression level at 6, 7, 8 and 10 weeks is shown in Figure 24) 
 
o Gjb3 (connexin 3 - dowregulated 4.40-fold): this gene belongs to a family of 
proteins that are component of gap junctions of endothelial cells and VSMc: gap 
junctions are implicated in the transmission of signals for the coordination in 
vasoconstriction and vasodilatation [116]. Alterations in the expression of this 
family of genes regulated by shear stress, hyperlipidaemia and TNF-α, is strongly 
implicated in atherosclerosis [115,116]. Other members of this family (Gja5 and 
Gjc2) are also modulated by ivabradines and are NF-κB target. (Gjb3 expression 
level at 6, 7, 8 and 10 weeks is shown in Figure 24) 
 
 
Figure 24: Diagrams showing expression levels of Gjb3 and Nppc ( blue dots: untreated mice at 6, 7, 8 and 
10 weeks ; red dots treated mice at 8 and 10 weeks). 
 
o Prkca (Protein kinase alpha - downregulated 1.5-fold): activation of this gene 
may increase endothelial cell permeability by disassembling of VE-cadherin 
junctions [117].  
 
o Ldlr1 (low density lipoprotein receptor 1 - downregulated 2.1-fold): Ldlr1 induces 
uptake of LDL in endothelial cells [49] and therefore its reduction would decrease 
endothelial cells permeability to LDL.  
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o Terc1 (telomerase RNA complex - upregulated 1.86-folds): telomerase length is 
associated to reduced senescence which leads to increased endothelium integrity 
[118]. 
 
- Apoptosis: 
 
o Dad1 (defender against cell death - upregulated 1.5-fold): Dad1 expression in 
transfected cells inhibits apoptosis in vitro, and his deletion induces apoptosis-
associated embryonic death in mice [119]. 
 
o Park 2 (parkin 2 - upregulated 1.5-fold): Park2 encodes for a component of a 
multiprotien E3 ubiquitin ligase complex. Loss of function in this gene inactivate 
the E3 ubiquitin ligase parkin, resulting in catecholaminergic neurodegeneration 
and a familial form of Parkinson disease. Its antiapoptotic duty is exerted by 
modulating the proaptotic function of Bax [120]. 
 
o Pax2 (paired box gene 2 - upregulated 2.4-fold): murine collecting duct cell line, 
which expresses high endogenous levels of Pax2, undergoes apoptosis when 
transfected with anti-sense Pax2. In contrast, HEK293 cells expressing exogenous 
Pax2 are protected against apoptotic death induced by caspase-2 [101]. 
 
o Olr1 (oxidized low density lipoprotein (lectin-like) receptor 1, LOX-1 - 
downregulated 3.2-fold): LOX-1 is not expressed in healthy endothelial cells but it 
is induced by elevated levels of LDL, inflammatory cytokines (TNF-α) and shear 
stress [121]. This receptor mediates the uptake of oxidized LDL, one of the first 
steps leading to endothelial dysfunctions and therefore high levels of Olr1 are 
strongly associated to atherosclerosis onset and progression [122]. Ox-LDL 
binding to LOX-1 decreases the expression of antiapoptotic proteins and then 
activates apoptotic signaling pathway caspase-9 and caspase-3 and finally results 
in apoptosis [121]. (Olr1 expression level at 6, 7, 8 and 10 weeks is shown in 
Figure 25) 
 
o Serpinb5 (maspin) (serine (or cysteine) peptidase inhibitor, clade B, member 5 - 
downregulated 5.02 fold). Maspin is a potent inhibitor of angiogenesis by 
regulating endothelial cell adhesion and migration [123]. Targeted expression of 
maspin in tumor vasculatures induces endothelial cell apoptosis [124]. Other 
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members of this family are also regulated by ivabradine. Additionally, other 
members of the family are regulated by shear stress in HUVEC [115]. (Serpinb5 
expression level at 6, 7, 8 and 10 weeks is shown in Figure 25) 
 
 
Figure 25: Diagrams showing expression levels of Olr1 and Serpinb5 ( blue dots: untreated mice at 6, 7, 8 
and 10 weeks ; red dots treated mice at 8 and 10 weeks). 
 
o Pon2 (paraonoxase - upregulated 1.55-fold): it is involved in the reduction of 
oxidative stress and apoptosis in endothelial cells [125,126] and adenoviral-
mediated human Pon2 expression in ApoE -/- protects against atherosclerosis 
[127]. 
 
- Inflammation: pro-inflammatory genes 
o ADAMTS7 (A Disintegrin And Metalloproteinase with Thrombospondin Motifs 
7 - downregulated 2.7-fold) and ADAMTS8 (A Disintegrin And 
Metalloproteinase with Thrombospondin Motifs 8 - downregulated 4.7-fold): 
ADAMTS genes are shear stress regulated and induced by inflammatory 
cytokines. ADAMTS are involved in degradation of glycoproteins components of 
glycocalix, important regulator of endothelium integrity [128]. Recently, it has 
been demonstrated ADAMTS7 pivotal role in early inflammatory kidney damage 
associated with aging [129]. ADAMTS7 is induced by TNF–α and supports 
migration of smooth muscle cells, which promotes collagen deposition into the 
plaques [130]. 
o Calca (calcitonin/calcitonin-related polypeptide, alpha – CGRP -downregulated 
3,5-fold); Calcb (calcitonin-related polypeptide, beta or CGRP2 - downregulated 
3.6-fold). Calca and Calcb are mediators of inflammation; Calca is involved in the 
accumulation of inflammatory cells in areas of inflammation [131]. It has been 
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shown that it is induced by TNF-α in the trigeminal ganglion neurons [132]. 
Additionally, Calca has pro-angiogenic action [133]. Calcb plays a pathogenic role 
in human joint inflammation and high levels of Calcb are measured in patients 
with osteoarthritis, gout and rheumatoid arthritis [134]. 
o Tnfsf18 (tumor necrosis factor (ligand) superfamily, member 18 - downregulated 
2.25-fold) encodes for Glucocorticoid-Induced TNF-Related Ligand (GITRL) 
which, interacting with Glucocorticoid-induced tumour necrosis factor receptor 
family related protein (GITR), mediates atherogenesis via the induction of pro-
atherogenic cytokines/chemokines, and destabilizes the atherosclerotic plaques 
through the induction of matrix metalloproteinase 9 (MMP-9) [135]. 
o Il1r2 (interleukin 1 receptor, type II - downregulated 2.5-fold), which pro-
inflammatory activity is exert through IL-1 activity regulation [136,137]. 
o Ptgs2 (prostaglandin-endoperoxide synthase 2 - COX2 - downregulated 1.9-
fold), which is expressed in atherosclerotic lesions in ApoE-/- mice and its 
inhibition prevents atherosclerosis [138,139]. It’s modulated by shear stress [140]. 
o Has1 (hyaluronan synthesis 1 - downregulated 2.2-fold) is a key molecule of the 
extracellular matrix. High levels are associated to atherosclerosis and restenosis. 
The cyclooxygenase (COX) products, prostacyclin and prostaglandin E(2), induce 
hyaluran synthesis in vitro by transcriptional up-regulation of Has2 and Has1 
[141]. 
o Tslp (thymic stromal lymphopoietin, downregulated 1.9-fold). Induced by ox-
LDL in HUVECs [142]. Target of Ang II via AT1 receptor/NF kappaB pathway 
[143]. 
o Cd55 (CD55 antigen (DAF) - downregulated 1.7-fold) which role in 
atherosclerosis is well established in ApoE (-/-)/CD55(-/-) mice [144]. 
o Clip4 (CAP-GLY domain containing linker protein family, member 4 - RSNL2 - 
dowregulated 2.7-fold). Reduced expression of this gene has been found in 
peripheral blood monocytes after treatment with anti inflammatory annexin A1-
derived peptide Ac1-25 [145]. Other members of Clip family are regulated by 
shear stress [146]. 
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- Inflammation: Anti-inflammatory genes 
o Esr1 and Esr2 (estrogen receptor 1 and 2 upregulated 1.9 and 1.5-fold 
respectively) are known to protect against inflammation. 
o Ffar3 (free fatty acid receptor 3 - GPR43 - upregulated 1.6-fold) which assumes 
an anti-inflammatory role through his SCFAs (short-chain fatty acids)-mediated 
activation [147].  
o Rgs4 (regulator of G-protein signaling 4 – upregulated 1,82-fold): it is involved 
in PPARdelta-mediated antiinflammatory mechanism, which inhibits angiotensin 
II-accelerated atherosclerosis [148]. It’s regulated by shear stress [146] and other 
members of Rgs family are modulated by ivabradine treatment. 
o Igf1 (insulin-like growth factor 1 - upregulated 1.3-fold): it reduces vascular 
inflammation, oxidant stress and decreases atherosclerotic plaque progression 
[149]. 
 
3.4 Pathways classification and enrichment analysis 
 
To identify underlying biological pathways, the differentially expressed genes were then 
analyzed using MetaCore™ (GeneGo, Inc., St. Joseph, MI, USA), a web-based 
computational platform designed for systems biology. Similar analyses were conducted 
using DAVID Bioinformatics Resources 6.7 (National Institute of Allergy and Infectious 
Diseases NIAID, NIH). 
These analyses allowed the identifications of enriched pathways. A pathway is considered 
enriched if it is more strongly represented in the list of differentially expressed gene than 
would be predicted by chance alone based on the total number of genes in the pathway 
proportionate to the number of genes on the array [150]. Some of these pathways are 
discussed below. 
Both MetaCore and DAVID (Table 3) analyses identified with high statistical significance 
the Notch pathway among the enriched pathways. The role of Notch pathway in the 
vascular system is well established [151] where it plays a pivotal function in preserving 
endothelium integrity by protecting endothelial cells from apoptosis, induced by conditions 
such as inflammation and ischemia [152–154]. Notch signalling activation by high 
pulsatile flow was associated with increased expression of antiapoptotic genes Bcl-2 and 
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Bcl-xL, and reduced apoptosis [155]. Ivabradine treatment induced upregulation of 
receptor Notch1, downregulation of ligand Jagged2, upregulation of transcriptional co-
activator of Notch Maml3 (mastermind-like 3), Notch-activated transcription factor Rbp-jk 
(recombination signal binding protein for immunoglobulin kappa J region), and Notch 
transcriptional target Hes5 (a major transducer of Notch signals in brain vascular 
development [156]). Our literature search identified modulation of two additional targets of 
Notch in our gene list, Nanog (2.5-fold upregulated) and Tlx2 (T cell leukemia, homeobox 
2 - 7-fold downregulated). In microglial cells, Nanog inhibits LPS-induced expression of 
pro-inflammatory cytokines by blocking NF-κB [157]. Tlx2 is inhibited by Notch1 
activation in amphioxus epidermal sensory neurons [158]. 
 
Pathway Name Gene Symbol Gene Name p-value  FC (Abs)  up/down 
Notch signaling pathway Notch1 Notch gene homolog 1 
(Drosophila) 
0,0037354 1,59442 up 
 Hes5 hairy and enhancer of split 5 
(Drosophila) 
0,0077782 3,34006 up 
 Jag2 jagged 2 0,0028323 2,21664 down 
 Maml3 mastermind like 3 (Drosophila) 0,0091298 1,52147 up 
 Rbp-jK recombination signal binding 
protein for immunoglobulin kappa 
J region 
0,0045399 1,5319 up 
 
Table 3: David analysis of individual components of the Notch signalling pathway significantly modulated 
 
MetaCore and DAVID analyses identified MAPK pathway as significantly modulated by 
ivabradine treatment (Table 4). MetaCore analysis indicates downregulation Prkca (protein 
kinase C, alpha), Grb2 (Growth factor receptor-bound protein 2), Araf (V-Raf Murine 
Sarcoma 3611 Viral Oncogene Homolog) and Mras (muscle and microspikes RAS), which 
suggests inhibition of phosphorylation cascade which activates ERK1/2 signaling. David 
analysis identified upregulation of Ppma1 (protein phosphatase 1A, magnesium dependent, 
alpha isoform) which encodes for a Ser/Thr protein phosphatase that inactivates ERK2 
[159]. Inhibition of ERK1/2 signalling leads to inhibition of NF-κB activity and therefore 
reduced inflammation and endothelial dysfunctions [116,160]. Of interest, ERK1/2 in 
endothelial cells is activated by shear stress [161]. Among the gene belonging to MAPK 
signaling pathway, we found Cacna1i (calcium channel, voltage dependent, alpha 1I 
subunit – upregulated 1,55-fold) which reduced expression was evaluated in VSMCs 
affected by atherosclerosis[162] and Cacng7 (calcium channel, voltage dependent, gamma 
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subunit 7 – upregulated 2,62-fold) whose expression is reduced in atrial and ventricular 
myocytes ischemic cardiomyopathy (Table 4 –David analysis)[163]. 
 
Pathway Name 
Gene 
Symbol 
Gene Name p-value  
FC 
(Abs)  
up/down 
MAPK signaling 
pathway 
Rasgrf2 
RAS protein-specific guanine nucleotide-
releasing factor 2 
9,54E-04 1,52216 up 
  Map3k14 
Mitogen-activated protein kinase kinase 
kinase 14 
0,001384 1,69729 up 
  Cacna1i 
calcium channel, voltage-dependent, alpha 
1I subunit 
0,0084313 1,55184 up 
  Cacng7 
calcium channel, voltage-dependent, 
gamma subunit 7 
0,0050768 2,61994 up 
  Dusp14 dual specificity phosphatase 14 0,0089758 1,64527 down 
  Il1r2 interleukin 1 receptor, type II 0,0070304 2,49972 down 
  Mapk8ip2 
mitogen-activated protein kinase 8 
interacting protein 2 
0,0034333 2,46491 up 
  Map3k8 
mitogen-activated protein kinase kinase 
kinase 8 
0,0030304 1,52362 down 
  Mras muscle and microspikes RAS 0,0064321 2,11209 down 
  Prkca protein kinase C, alpha 0,0046626 1,52153 down 
  Ppm1a 
protein phosphatase 1A, magnesium 
dependent, alpha isoform 
1,09E-04 2,40045 up 
  Rras2 
related RAS viral (r-ras) oncogene homolog 
2 
0,0024018 1,59421 down 
 
Table 4: David analysis of individual components of the MAPK signaling pathway significantly modulated 
 
Lastly MetaCore and DAVID analyses identified enrichment of sterol metabolic processes 
in our gene List 2 (Table 5). Ldlr and Hmgcs1 (3-Hydroxy-3-Methylglutaryl-CoA 
Synthase) expression is regulated by SREBP1 (sterol regulatory element- binding proteins) 
a family of transcription factors activated by low levels of sterols and by shear stress; while 
laminar flow induces only a transitory activation of SREBP1, under disturbed flow the 
activation is prolonged [49]. Of interest, Ch25h (downregulated by the treatment) plays a 
role in inflammation in addition to the more established role in the regulation of cholesterol 
homeostasis [164]. These gene encodes for an enzyme which catalyze the formation of 25- 
hydroxycholesterol from cholesterol, which increases macrophage foam cell formation in 
Apoe -/- mice [165].  
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Pathway Name Gene 
Symbol 
Gene Name p-value  FC 
(Abs)  
up/down 
Cholesterol metabolic process Hnf1a HNF1 homeobox A 0,0092684 2,07714 up 
 Nsdhl NAD(P) dependent steroid 
dehydrogenase-like 
0,0053965 1,94195 down 
 Ch25h cholesterol 25-hydroxylase 0,0021805 1,81742 down 
 Cyp46a1 cytochrome P450, family 46, 
subfamily a, polypeptide 1 
0,0094426 1,87193 up 
 Cyp51 cytochrome P450, family 51 0,0034192 2,26716 down 
 Lepr leptin receptor 0,0083405 1,95811 up 
 Ldlr low density lipoprotein receptor 0,0052362 2,13844 down 
 Hmgcs1 similar to Hmgcs1 protein; 3-
hydroxy-3-methylglutaryl-
Coenzyme A synthase 1 
4,45E-04 3,28802 down 
 Sc4mol sterol-C4-methyl oxidase-like 0,0072525 1,6151 down 
 Esr1 estrogen receptor 1 (alpha) 0,0047946 1,97645 up 
 Nr1h4 nuclear receptor subfamily 1, 
group H, member 4 
0,001839 2,24837 down 
 
Table 5: David analysis of individual components of the cholesterol metabolic process significantly 
modulated 
 
3.5  Ivabradine antagonizes NF-κB activation of target genes and Angiotensin II 
activation  
 
In Table 6 are shown 10 genes that are downregulated by ivabradine and are induced (the 
same gene or a closely structurally/functionally related one) by nuclear factor KappaB 
(NF-κB). In the contest of atherosclerosis, activation of NF-κB is mediated by numerous 
stimuli, including local factors (such as vascular injury and wall thickness-mediated 
hypoxia), oxidative stress (Ox-LDL, homocysteine), cytokines (TNFα, IL-1), angiotensin 
II (AngII) , integrin/matrix pathway and hemodynamic forces [166–169]. Furthermore, 
NF-κB modulates expression of many genes involved in the initiation and progression of 
atherosclerotic lesions, such as VCAM-1, ICAM-1, P- and E-selectin and MCP-1. 
Activated nuclear NF-κB was detected in macrophages and vascular smooth muscle cells 
in atherosclerotic regions in humans and animal models [168]. The role of NF-κB in 
endothelial cells was elucidated by experiments showing that endothelial cells in the 
atheroprone aortic arch show higher levels of different NF-κB components compared with 
atheroprotected regions [168]. Moreover, endothelium-restricted inhibition of NF-κB 
reduces plaque formation in ApoE -/- mice fed with a cholesterol-rich diet [170]. 
The table was obtained by comparing the genes in List 2 with known NF-κB targets listed 
in the Boston University database (http://www.bu.edu/nf-kb/gene-resources/target-genes). 
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Among these genes we found Wnt7a (MMTV integration site 7A - downregulated 5.18-
fold): this gene is an activator of Wnt signalling. Wnt-stimulates angiogenesis and it is a 
very well known Notch signaling modulator [171]. In VSMc, Wnt7a is induced by TNF α 
and it has been implicated in aorta calcification in diabetic Ldlr -/- mice [172]. Another 
gene listed in Table 6 is Slc6a4s (solute carrier family 6 (neurotransmitter transporter, 
serotonin), member 4 - downregulated 3.41-fold): this gene is involved in the uptake of 5-
hydroxytryptamine (5-HT, serotonin) a well characterized neurotransmitter in the central 
nervous system which also plays diverse roles in the circulation by regulating vascular tone 
and platelet function. An elevated plasma concentration of 5-HT is a common feature of 
cardiovascular disease often associated with enhanced platelet activation and thrombosis. It 
has been shown that down-regulation of the serotonin transporter on the platelet surface 
may counteract the pro-thrombotic influence of elevated levels of serotonin in plasma 
[173]. Other members of the same family are also modulated by ivabradine and other genes 
belonging to this family are regulated by shear stress and are NF-κB target [115]. 
 
Gene name 
(ivabradine 
modulated)
FC (abs) Regulation Function
Gene name (Nk-
kb modulated)
NF-kB 
Regulation
References
CD55 antigen 
(CD55)
1,77 down
Cell surface 
complement 
regulatory 
protein
CD55 up
Izban MG et al. PLoS
One. 
2012;7(11):e49318
Inflammation
PTGIS 
prostaglandin 
synthase
up
Yokoyama C et al.
Genomics. 1996 Sep
1;36(2):296-304
Inflammation
PGES, 
prostaglandin E  
synthase
up
Zhou A et al.
Oncogene. 2003 Apr
3;22(13):2054-64
 Hyaluronan 
synthase1 (Has1)
2,23 down
Synthesizes 
hyaluronic 
acid
HAS1 up
Saavalainen K et al. J
Biol Chem. 2007 Apr
13;282(15):11530-9
Interleukin 1 
receptor, type II 
(Il1r2)
2,50 down inflammation IL-1RN up
Smith MF Jr et al. J
Immunol. 1994 Oct
15;153(8):3584-93
Oxidized low 
density lipoprotein 
(lectin-like) 
receptor 1 (Olr1) 
Lox1
3,20 down
receptor for 
oxidized low 
density 
lipoprotein
LOX-1 up
Nagase M et al. J Biol
Chem. 1998 Dec
11;273(50):33702-7
Solute carrier 
family 6 
(neurotransmitter 
transporter, 
serotonin), 
member 4 (Slc6a4)
3,42 down
(neurotransmit
ter transporter, 
serotonin)
SLC6A6 
(neurotransmitter 
transporter, 
taurine)
up
Mochizuki T et al.
FEBS Lett. 2005 Jun
6;579(14):3069-74
GJB1
Yamamoto T et al. Exp
Cell Res. 2004 Oct
1;299(2):427-41
GJA1
Florian Alonso et al.
Cardiovascular 
Research (2010) 87,
166–176
Serine (or 
cysteine) 
peptidase inhibitor, 
clade B, member 5 
(Serpinb5)
5,03 down
Endothelial 
cells 
apoptosis 
inducer
SERPINE2 up
Suzuki S et al. FEBS
Lett. 2006 May
29;580(13):3257-62
Wingless-related 
MMTV integration 
site 7A (Wnt7a)
5,18 down
Induction of 
angiogenesis
WNT10B up
Katoh M. Int J Mol
Med. 2007
Apr;19(4):699-703
T-cell leukemia, 
homeobox 2 (Tlx2)
7,09 down
homeobox 
protein
TLX2 up
Zhang M et al. Vasc
Med. 2008
Aug;13(3):239-45
Communicatio
ns between 
endotheliial 
cells
up
Prostaglandin-
endoperoxide 
synthase 2 (Ptgs2 
COX-2)
1,91 down
Gap junction 
protein, beta 3 
(Gjb3)
4,40 down
 
Table 6: List of NF-κB related genes modulated by ivabradine 
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Our analysis identified 9 genes that are modulated in opposite direction by Angiotensin II 
and ivabradine (Table 7). Ang II is activated by dyslipidemia and it is a potent inducer of 
atherosclerosis [174] by enhancing the release of growth factors (e.g. PDGF, TGF-β, IGF-
I), chemokines (MCP-1) and cytokines (IL-6, IL-1). Ang II can also alter the extracellular 
matrix remodeling via activation of metalloproteinases (MMP-2, MMP-9) and induce a 
procoagulant state. Ang II can increase expression of adhesion molecules (E-selectin, 
VCAM-1, and ICAM-1), enhance the recruitment of local macrophages into the 
atherosclerotic plaque and, not least, it can augment endothelial dysfunction and 
inflammation promoting NADPH oxidase-mediated ROS production, which in turn 
reduces NO bioavailability and promotes oxidation of LDL [31,175]. Our results confirm 
and expand Custodis et al. observations in Apo E-deficient mice in which ivabradine 
improves vascular compliance also by antagonizing Ang II activation [100].  
 
Gene name 
(ivabradine 
modulated)
FC (abs) Regulation Function
Angiotensin II 
regulation 
Reference
low density lipoprotein 
receptor (Ldlr)
2,14 down
Binds LDL and transpots it into 
cells by endotcytosis 
Up 
Sendra J et al. Cardiovascular
research 2008 (LDL receptor
related protein in VSMc)
muscle and microspikes 
RAS (Mras)
2,11 down
Acts downstream of TNF alpha in 
causing apoptosis
Up 
http://betacellgenebank.ulb.ac.be/
page/GeneMore/display/?seq_id
=D89863
oxidized low density 
lipoprotein (lectin-like) 
receptor 1 (Olr1)
3,20 down
Endothelial receptor that mediates 
uptake of oxLDL and promotes 
plaque's formation.
Up 
Henning Morawietz et al.
Circulation. 1998;98[suppl I]:I-521
prostaglandin-
endoperoxide synthase 
2 (Ptgs2)
1,91 down
Key enzyme in prostaglandin 
biosynthesis. Promotes 
inflammation and atherosclerosis
Up 
Schlondorff D et al. Am J Physiol.
1987; 253: C113–C120
regulator of calcineurin 1 
(Rcan1)
1,53 down
Regulator of calcineurin which 
madiates pathological vascular 
wall remodelling and VSMCs 
migration
Up 
Esteban V et al. J Exp Med. 2011
Sep 26;208(10):2125-39
thymic stromal 
lymphopoietin (Tslp)
2,00 down
Protein belonging to the cytokine 
family and It’s upregulated in 
atherosclerosis
Up 
Hui Zhao et al.Cell Physiol
Biochem. 2012 Nov 16;30
(6):1383-1397  
T-cell leukemia, 
homeobox 2 (Tlx2)
7,09 down
Induced by BMP2 which is 
activated by AngII
Up Zhang M et al. Vasc. Med 2008
phosphodiesterase 3A, 
cGMP inhibited (Pde3a)
1,60 up
PDE3A has cardioprotective 
effects against AngII-induced 
cardiac injury 
Negative 
regulator of 
AngII
Masayoshi Oikawa et al.
Circulation. 2012; 126: A9719
regulator of G-protein 
signaling 4 (Rgs4)
1,83 up
RGS4 has been reported to be 
negative regulator of AngII 
signaling through the AT1 receptor 
Negative 
regulator of 
AngII
Yasunori Takata et al. Proc Natl
Acad Sci U S A. 2008 Mar
18;105(11):4277-82
 
Table 7: List of Angiotensin II related genes modulated by ivabradine 
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3.6 qRT-PCR validation of microarray analysis results 
 
To validate the microarray results, qRT-PCR was carried out to measure the expression 
levels of some of the genes affected by the treatment. Among the genes identified, we 
focused on Nppc (one of the most sensitive shear-stress responsive gene, downregulated 
5.7-fold), and Olr1/LOX-1 (for the pivotal role in atherosclerosis, downregulated 3.2-fold)  
The reduction of Nppc mRNA by ivabradine was confirmed in two groups of RNAs. In the 
remaining RNA utilized for the main microarray experiment (Figure 26) and in RNA not 
included in microarray analysis (Figure 27).  
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Figure 26: qRT-PCR analysis of Nppc expression before and after 2 (left panel) or 4 (right panel) weeks 
treatments with ivabradine (30mg/kg/day in drinking water). Each point is a mean value of 3 pool of RNA 
(each pool is a collection of two ApoE -/- mice aortic arch endothelial cells enriched-RNA, previously 
analyzed by microarray). Relative changes in mRNA expression levels were calculated according to the 2
-
ΔΔCt
 method using RPL13 as reference gene (*** p < 0.0001). T: treated; NT: untreated. 
 
In this first analysis (Figure 26), we found a highly significant reduction (87.6%) in Nppc 
mRNA, following two weeks of ivabradine treatment (8NT Vs T). This reduction was even 
greater (92,3%) after four weeks of ivabradine treatment (10NT Vs 10T). The ivabradine-
mediated Nppc mRNA reduction was also confirmed in RNA from the second group 
(Figure 26). In order to demonstrate the effect of ivabradine on Olr1 gene expression, we 
could only rely on RNAs from the second group. As shown in Figure 27, Olr1 was 
downregulated after two weeks of treatment (68% of reduction compared to untreated 
group). This reduction was even more evident in 10 weeks old ApoE -/- mice aortic arch 
endothelial cells enriched-RNA, following four weeks of treatment (92%). 
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Figure 27: qRT-PCR analysis of Nppc (upper panel) and Olr1 (bottom panel) expression before and after 2 
or 4 weeks treatments with ivabradine (30 mg/kg/day in drinking water). Each point is a pool of two ApoE -/- 
mice aortic arch endothelial cells enriched-RNA. Relative changes in mRNA expression levels were 
calculated according to the 2
-ΔΔCt
 method using RPL13 as reference gene. (*** p < 0.0001). T: treated; NT: 
untreated. 
  
3.7  En face analysis of endothelium: endothelial dysfunction and Hes5 
 
This analysis aimed to characterize the effect of ivabradine treatment in counteracting 
endothelial dysfunction in ApoE-/- mice.  
We first tried to measure endothelial dysfunction in 10 weeks old ApoE-/- mice (n=4) by 
en face analysis of VE-Cadh, a cell-cell adhesion glycoprotein which controls the 
intracellular junctions integrity [176]. As shown in Figure 28, no lesions were visible in 
endothelium of untreated ApoE-/- mice. We tried to perform again the same measurement 
of endothelial integrity grade, in untreated 18 weeks old ApoE-/- mice (n=4). Even in this 
case no dysfunctions were detected (data not shown).    
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Figure 28: VE-cadherin staining in aortic arches arch lesser curvature of 10 weeks old ApoE -/- untreated 
mice. Images acquired with Zeiss Confocal microscope (magnification 40X) (n=4;  images from 5 fields) 
 
Based on these results, in order to increase our chances to detect differences in in VE-Cadh 
staining, between treated and untreated mice, 5 weeks old ApoE-/- mice (n=10) were 
treated or not with ivabradine (30 mg/kg/day) beginning from 6 weeks of age, and were 
sacrificed when they were 25 weeks old, age at which plaques have been shown in mice 
fed a chow-diet [85]. 
In lower arches of untreated mice we observed extensive areas of endothelium covered 
with atheromatous plaques. The endothelium outside the plaque was heavily damaged, as 
indicated by the high disorganization of VE-Cadh (images from different field are shown 
in Figure 29).  
 
 
Figure 29: VE-cadherin staining in aortic arches lesser curvature of 25 weeks old ApoE -/- untreated mice. 
Images were acquired with Zeiss Confocal microscope (magnification 40X) (n=5; images from 5fields) 
 
There were no atheromatous plaques in the lesser curvature of aortic arch in the treated 
group and the endothelium was mostly intact (images from different fields are shown in 
Figure 30). In order to obtain a quantitative measure of endothelium damage, we measured 
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(in four different fields for each section) by Image J the percent area with endothelial 
damage.  
 
Figure 30: VE-cadherin staining in aortic arches lesser curvature of 25 weeks old ApoE -/- treated mice (30 
mg/kg/day in drinking water). Images were acquired with Zeiss Confocal microscope (magnification 40X) 
(n=5; images from 5fields) 
 
As shown in Figure 31 there was a significant difference in the percentage of damaged 
endothelium between the two groups of mice (untreated 91,74 ± 4,08 vs treated 28,98 ± 
7,28). 
 
Figure 31: Representative staining for Ve-Cadherin in 25 weeks old ApoE -/- aortic arch lesser curvature, 
following 19 weeks of treatment with (A) ivabradine (30 mg/kg/day in drinking water) or (B) no treatment. 
(40X magnification). (C) Difference in area with endothelium damages between treated and untreated mice 
(*** p < 0.0001). 
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Consistently with our microarray data suggesting a protective effect of ivabradine on the 
endothelium of the aortic arch, 19 weeks of treatment with ivabradine slowed down 
endothelial dysfunctions in the lesser arch of the aortic arch. In the same age groups 
mentioned so far, we tried to validate the effect of ivabradine in modulating Hes5. In 10 
weeks old ApoE-/- mice, following 4 weeks of ivabradine treatment (30 mg/kg/day), 
immunofluorescence analysis for Hes5 was conducted in longitudinal sections of frozen 
aortic arch fixed in ice cold acetone. Image analysis showed no differences in the 
expression levels of Hes5 (Figure 32) in the endothelial layer of the aortic arch of 
ivabradine-treated mice compared with untreated animals. 
 
 
Figure 32: Hes5 (green) and VE-cadherin (red) staining in 10 weeks old ApoE-/- mice aortic arches 
following 4 weeks of treatment with (A) ivabradine (30 mg/kg/day in drinking water) or (B) no treatment. 
Images acquired with Zeiss Confocal microscope at 40X magnification. (C) Difference in Hes5 fluorescence 
values between treated (n=5) and untreated (n=5) mice. Results are expressed as mean ± SEM. 
 
In the same 25 weeks old ApoE-/- mice, following 19 weeks of ivabradine treatment, used 
for endothelial dysfunction analysis in the inner curvature of aortic arch, we performed 
Hes5 staining in the upper side of aortic arch, which undergoes the same hemodynamic 
forces of the inner curvature of aorta. In the upper arch, as seen in the lower one, the 
endothelium was more extensively damaged in the untreated mice, making Hes5 detection 
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very complicated and his quantification impossible to achieve, due to the limited number 
of images taken in this samples. Nonetheless, as shown in Figure 33, Hes5 staining seemed 
to be more intense in upper arch of treated mice compared to untreated mice, data 
consistent with ivabradine-mediated Hes5 upregulation observed in microarray analysis. 
 
 
Figure 33: Representative staining for Hes5 (green) and VE-cadherin (red) in aortic arches upper curvature 
of 25 weeks old ApoE-/- mice aortic arches following 19 weeks of treatment with (A) ivabradine (30 
mg/kg/day in drinking water – n=5) or (B) no treatment (n=5). Images acquired with Zeiss Confocal 
microscope at 40X magnification.  
 
4. The role of shear stress in ivabradine-mediated protective gene expression profile. 
Does ivabradine alter the shear stress forces on the endothelium? 
 
The results of our experiments show that, in dyslipidaemic mice fed a standard chow-diet, 
treatment with ivabradine induces an atheroprotective gene expression profile in the 
endothelium of the aortic arch characterized by changes in the expression of genes 
involved in the modulation of ox-LDL uptake, cell permeability, apoptosis, inflammation 
and, as previously mentioned, reduces the degree of damage to the endothelium of ApoE -
/- mice aortic arch.  
Many of the genes listed in Table 8, thoroughly discussed above, are shear stress sensitive, 
supporting the hypothesis that ivabradine may exert its protective role through the 
regulation of shear stress.  
 
63 
Gene Name (ivabradine modulated) FC (Abs) p-value
Regulation by 
ivabradine treatment
Shear Stress modulation 
Reference
hyaluronan synthase1 (Has1) 2,23 0,0063 down (Mohamadzadeh et al. 97-108)
Natriuretic peptide type C (Nppc) 5,73 0,0018 down
(Zhang, Xiao, and Diamond 419-
26)
Low density lipoprotein receptor (Ldlr) 2,14 0,0052 down (Liu et al. 76-81)
Notch gene homolog 1 (Notch1) 1,59 0,0037 up
Jagged 2 (Jag2) 2,22 0,0028 down
T-cell leukemia, homeobox 2 (Tlx2) 7,09 0,0001 down
CAP-GLY domain containing linker protein family, 
member 4 (Clip4)
2,73 0,0058 down
regulator of G-protein signaling 4 (Rgs4) 1,83 0,0090 up
 Protein kinase C, alpha  (Prkca) 1,52 0,0047 down
prostaglandin-endoperoxide synthase 2 (Ptgs2) 1,91 0,0060 down (Passerini et al. 2482-87)
 Serine (or cysteine) peptidase inhibitor, clade  B, 
member 5 (Serpinb5) 
5,02 0,0013 down
 Solute carrier family 6 (neurotransmitter 
transporter, serotonin), member 4 (Slc6a4) 
3,42 0,0002 down
dual specificity phosphatase 14 (Dusp14) 1,65 0,0090 down
interleukin 1 receptor, type II (Il1r2) 2,50 0,0070 down
mitogen-activated protein kinase 8 interacting 
protein 2 (Mapk8ip2)
2,46 0,0034 up
mitogen-activated protein kinase kinase kinase 8 
(Map3k8)
1,52 0,0030 down
related RAS viral (r-ras) oncogene homolog 2 
(Rras2)
1,59 0,0024 down
Wingless-related MMTV integration site 7A  
(Wnt7) 
5,17 0,0079 down
Gap junction protein, beta 3 (Gjb3) 4,40 0,0066 down
Oxidized low density lipoprotein (lectin-like)  
receptor 1 (Olr1, LOX1) 
3,19 0,0036 down
sterol-C4-methyl oxidase-like (Sc4mol) 1,62 0,0073 down
A disintegrin-like and metallopeptidase  with 
thrombospondin type 1 motif, 8 (Adamts8) 
4,67 0,0068 down
leptin receptor (Lepr) 1,96 0,0083 up
Paraxonase 2 (Pon2) 1,55 0,0021 up
Parkinson disease (autosomal recessive,  
juvenile) 2, parkin  (Park2) 
1,52 0,0052 up
HNF1 homeobox A (Hnf1a) 2,08 0,0093 up
similar to Hmgcs1 protein; 3-hydroxy-3-
methylglutaryl-Coenzyme A synthase 1 (Hmgcs1)
3,29 0,0004 down
RAS protein-specific guanine nucleotide-
releasing factor 2 (Rasgrf2)
1,52 0,0010 up
Mitogen-activated protein kinase kinase kinase 
14 (Map3k14)
1,70 0,0014 up
NAD(P) dependent steroid dehydrogenase-like 
(NSDHL)
1,94 0,0054 down
muscle and microspikes RAS (Mras) 2,11 0,0064 down
 ATP-binding cassette, sub-family B (MDR  TAP), 
memeber 1A (Abcb1a)
1,93 0,0028 down (Vion et al. 1323-33)
 Cholesterol 25-hydroxylase (Ch25h) 1,82 0,0022 down (Keuschnigg et al. e74293)
 A disintegrin-like and metallopeptidase with 
thrombospondin type 1motif, 7 (Adamts7) 
2,75 0,0042 down (Bond et al. 366-72)
(Hohberg et al. 350-61)
(White et al. 2841-48)
(Dolan et al. C1109-C1118)
(Brooks, Lelkes, and Rubanyi 
27-41)
(Peters et al. 25-33)
(Dai et al. 14871-76)
(Andersson et al. 441-52)
(Avvisato et al. 2672-82)
(Li and Mehta 566-68)
 
Table 8: List of ivabradine-modulated genes shear stress sensitive 
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Among the pathways highlighted in the previous analysis, we found that ivabradine 
modulated Notch signalling. The Notch pathway has been shown to be upregulated and 
activated by laminar shear stress in vitro [177] but since there are scarce data on the in vitro 
effect of low and oscillatory shear stress on Notch signalling and on the regulation of 
Notch by shear stress in vivo, we attempted to better define the molecular details of Notch 
signaling modulation by shear stress.  
 
4.1 Notch signalling modulation by in vitro shear stress system 
 
The aim of this experiment was to mimic in vitro, by using an ex vivo culture system 
(cone-and-plate viscometer), the shear stress patterns found in different regions of mouse 
aorta, and to study their effect on Notch gene expression profile. Specifically, to simulate 
low and oscillatory shear stress, peculiarity of the aortic arch, we used a grooved cone and 
low shear stress force (D-flow-50 rpm-12 dynes/cm
2
), whereas to imitate the laminar flow 
of thoracic aorta, we used a smooth cone and high shear stress force (S-flow-200 rpm-50 
dynes/cm
2
). After a 24-hours exposition to shear stress, images of HUVECs were taken to 
evaluate the effect of shear stress on cells shape, an endothelial morphological response to 
flow and the resultant of shear stress [178–180]. As shown in Figure 34, HUVECs exposed 
to S-flow were elongated with the major axis aligned in the direction of flow, whereas 
those exposed to D-flow were round in shape with a not well defined axis direction. 
 
 
Figure 34: Representative images of HUVECs subjected to (A) D-flow or (B) S-flow (Images acquired at 4X 
objective), compared to images of endothelium (Ve-Cadherin in red) of whole mount preparation of mouse 
aortic arch (C) and thoracic aorta (D) (Images acquired with Zeiss Confocal microscope at 40X 
magnification).  
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RNA from HUVECs was extracted and qRT-PCR was carried out to measure the 
expression levels of Notch components. Data obtained showed a significant increase of 
Hey1 (3.9-fold), Hey2 (3.9-fold), Hes1 (2.74-fold), Notch1 (2.37-fold), Notch2 (2.59-fold) 
and Jagged-1 (6.31-fold) mRNAs  levels in S-flow, compared to static control (Figure 35).  
 
Figure 35: HUVECs were subjected to S-flow and D-flow for 24 hours. Total RNA was extracted and qRT-
PCR analysis for (A) Hey1, (B) Hey2, (C) Hes1, (D) Notch1, (E) Notch2, (F) Notch4, (G) Jagged-1, (H) 
Jagged-2 and (I) Nppc genes expression was performed. mRNA expression levels were calculated according 
to the 2
-ΔΔCt
 method using RPL13 as reference gene. HUVECs under static flow were used as control. Results 
are expressed as mean ± SEM of three independent experiments, each performed in triplicate (*** p < 
0.0001; ** p< 0.001). 
 
An increase of the Hey1, Hey2, Hes1, Notch1, Notch4 and Jagged-1 mRNA levels was 
also found in D-flow condition when compared to static control. This data is not surprising 
since it has been shown that in HUVECs there are sets of genes regulated by laminar and 
disturbed flow stimulations in a similar pattern when compared to a static control [115]. 
Nonetheless, there is no denying that Notch components, except Hes1 in which difference 
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did not achieve significance, exhibited high mRNA levels in HUVECs in S-flow compared 
to D-flow condition. No differences in gene expression was found for Notch4 and Jagged-2 
under different shear stress conditions. Along with Notch, Nppc was analyzed, which is a 
well-known laminar shear stress-induced gene [114,181]. As expected, Nppc was highly 
upregulated by S-flow (162-fold) and, albeit to a lesser extent, by D-flow stimulation (5-
fold) (Figure 35).  
HUVECs after 24h under static, D- and S- flow were fixed in 4% PFA and stained for 
Notch1 and Notch4. Microscopy analysis was carried out to measure protein levels. 
As shown in Figure 36, in D-flow treated cells we found reduction of Notch1 and Notch4 
compared to S-flow and Static control. 
 
 
 
Figure 36: (A) Representative microscopy images of HUVECs (Static, S- and D-flow) stained for Notch1 
and 4 (red) and VE-cadherin (green). Images acquired with Zeiss Confocal microscope at 40X magnification. 
(B) Difference in Notch1 and Notch 4 fluorescence values between HUVECs subjected to the three different 
flows (static, S- and D- flow). Results are expressed as mean ± SEM of three independent experiments. (*** 
p < 0.0001). 
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These data suggest a differential Notch regulation by different shear stress conditions, 
confirming that laminar shear stress induces Notch activation [182] compared to low and 
oscillatory shear stress.  
 
4.2 Effect of shear stress on gene expression in endothelium of C57BL6/J mice aortic 
arch and thoracic aorta 
 
Since we demonstrated that Notch is regulated by shear stress in vitro, we evaluated 
differential Notch expression profile between regions of mice aorta subjected either to 
laminar shear stress (thoracic aorta) or to low and oscillatory shear stress (aortic arch). 
We first qualitatively evaluated protein levels of Notch receptors (Notch1 and Notch4) and 
Notch target genes Hey2 and Hes5 (upregulated by ivabradine treatment - 3,34-fold) in the 
endothelium of whole mount preparations of aortic arch and thoracic aorta of C57BL6/J 
mice. Protein levels of Notch4, Hes5 and Hey2 were lower in the aortic arch compared to 
the thoracic aorta. Notch1 protein levels were similar between the two portions of mice 
aorta (Figure 37). 
 
 
Figure 37: Rapresentative images showing staining of the endothelium of the aortic arch lesser curvature and 
of thoracic aorta from C57BL6/J mice for Notch 1, Notch 4, Hes5 and Hey2 (green). Endothelial cells 
membrane was identified by staining for VE-Cadherin (red). Images acquired with Zeiss Confocal 
microscope at 40X magnification  
 
We also measured their mRNA levels in endothelium-enriched RNA isolated from those 
regions (n=7). Quantitative RT-PCR showed a significant reduction of Hey2 (0.70-fold) 
and Notch4 (0.78-fold) mRNAs in the aortic arch, indicating an activation of their gene 
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expression in the thoracic portion of aorta. The strongest activation was measured for Hes5 
mRNA, which was upregulated 11-fold in thoracic aorta compared to aortic arch. There 
were no clear differences between aortic arch and thoracic aorta in Notch 1 mRNA levels, 
which resembles his protein levels evaluated by en-face analysis (Figure 38). 
 
Figure 38: qRT-PCR histograms showing the differences in mRNA expression levels for Notch4, Notch1, 
Hes5 and Hey2 between aortic arch and thoracic segment. Relative changes in mRNA expression were 
calculated according to the 2
-ΔΔCt
 method using RPL13 as reference gene (3 experiments, ***P<0.001).  
 
Along with Notch components, we measured the expression of Nppc and Olr1 genes: we 
found a significant reduction of expression of these two genes in endothelium-enriched 
RNA isolated from the thoracic aorta compared to aortic arch (Figure 39).  
 
Figure 39: qRT-PCR histograms showing the differences in mRNA expression levels for Nppc and Olr1 
between aortic arch and thoracic segment. Relative changes in mRNA expression were calculated according 
to the 2
-ΔΔCt
 method using RPL13 as reference gene (3 experiments, ***P<0.001).  
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Our Nppc data of qRT-PCR analysis above are in contrast with those obtained by in vitro 
flow experiments, in which we found a strong activation of Nppc by atheroprotective 
laminar shear stress. Passerini and collaborators had pointed out that there are some 
discrepancies between genes identified as modulated by shear stress in other in vitro 
studies, and the same genes which they found out as differentially expressed between 
lesion-prone areas and protected sites of adult porcine aorta [135]. Actually, these 
differences could be explained by the disparate systems used in in vitro experiments to 
simulate shear stress, the different type of cell origins and the sensitivities of techniques 
used. Mostly, it could be quite intricate to compare a long-adapted condition which occurs 
in the endothelium of blood vessels with a short-time simulation of shear stress patterns in 
vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4) CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
This study shows that in dyslipidemic mice fed a standard chow-diet, treatment with 
ivabradine induces a “protective” gene expression profile in the endothelium suggestive of 
a reduction of LDL uptake, endothelial cells permeability, oxidative stress and apoptosis. 
Moreover ivabradine could regulate the endothelium inflammatory status, by both 
upregulating anti-inflammatory genes and reducing expression of pro-inflammatory genes. 
It is also noteworthy that the genes we found modulated by ivabradine treatment are 
regulated in the opposite direction by Nf-κB. Nf-κB is “primed” for activation in 
atheroprone regions and this “priming” effect is determined by local shear stress which 
causes an increase in the expression of NF-κB components [168]. Ivabradine didn’t alter 
the mRNA expression levels of NF-κB components, indicating that the drug may inhibit 
NF-κB action by affecting downstream pathways. Similarly, the analysis of ivabradine-
modulated genes shows inhibition of AngII-mediated signalling. AngII signalling is 
activated under dyslipidemic conditions [183] and it has been shown that in ApoE -/- mice, 
ivabradine antagonizes AngII also by reducing the mRNA of the AT-1 receptor in the 
vascular wall [99]. We didn’t found changes in the expression levels of AT-1 in treated 
mice, suggesting that, as with NF-κB, ivabradine may antagonize AngII-mediated 
signalling by affecting downstream pathways. Of interest, we found MAPK pathways as 
significantly modulated by ivabradine treatment, with changes suggestive of an inhibition 
of ERK1/2 signalling. Since both NF-κB and AngII require the activation of the ERK1/2 
[116,160], the inhibition of MAPK-related pathways by ivabradine could determine the 
observed inhibition of NF-κB- and AngII-mediated signalling.  
 
Many of the genes modulated by ivabradine treatment, some of which belong to MAPK, 
NF-κB, AngII pathway and cholesterol metabolic processes, are shear stress sensitive and 
this evidence suggests that modulation of shear stress could be part of ivabradine 
mechanism of protection exerted in aortic arch endothelium of our animal model of 
atherosclerosis. Our data are in agreement with a recent report showing that ivabradine 
could alter shear stress at the inner curvature of mice aorta by increasing shear stress 
magnitude and reducing oscillatory index, along with induction of protective eNOS 
expression and reduction of inflammatory VCAM-1 [184]. Among the pathways which are 
modulated by ivabradine and are shear stress sensitive we found Notch signalling. Our in 
vitro flow experiments showed a sustained upregulation of Notch signalling by 
atheroprotective laminar shear stress. Our in vivo analyses on mice aorta confirm the 
activation of Notch signalling components by the atheroprotective laminar shear stress and 
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provide the first in vivo evidence of differences in expression levels of Notch components 
between different regions of mouse aorta.  
 
In agreement with these data, suggesting a protective effect of ivabradine on the 
endothelium of the aortic arch, 19 weeks of treatment with ivabradine significantly reduces 
endothelium damage and slows down plaque formation in the lesser curvature of aortic 
arch of ApoE-deficent mice, along with preliminary evidences of higher levels of Hes5 in 
the upper aortic arch of treated mice compared to untreated ones. Notch activation by 
ivabradine treatment was also highlighted by microarray data, indicating upregulation of 
Hes5 and several Notch signalling components. It remains to be established whether 
downregulation of Notch signalling in the aortic arch could be involved in atherosclerosis 
onset and/or progression. A possible role of Notch in the context of inflammation and 
apoptosis, which underlie the first step of atherosclerosis, could derive from his interaction 
with pathways known to be involved in this process. A link between shear stress and 
Notch–mediated EC apoptosis has been demonstrated in vitro in bovine retinal endothelial 
cells, where Notch signalling activation by high pulsatile flow was associated with 
increased expression of antiapoptotic genes Bcl-2 and Bcl-xL, and reduced apoptosis 
[180]. In the context of inflammation, NF-κB inhibition by activation of Notch signaling 
has been described. In macrophages, Toll like receptor (TLR4) activation by LPS 
upregulates Notch target Hes5 which in turns modifies the pattern of expressed cytokines 
from pro- to anti-inflammatory activity. In these cells, activation of Notch1 mediates 
ERK1/2 inactivation which inhibits NF-κB induction of inflammatory cytokines [184]. In 
endothelial cells TNF-α-induced Notch4 and Hes1 downregulation is associated with NF-
κB-mediated I-CAM induction [153]. A recently published study has shown that Notch1 
activation in endothelial cells downregulates miR155, an activator NF-κB [185]. Thus, 
activation of Notch could therefore underlie the observed Nf-κB inhibition following 
ivabradine treatment.  
 
In conclusion this study provides strong evidence of ivabradine-mediated induction of a 
protective gene expression profile in the endothelium of aortic arch of ApoE-deficient 
mice. Among the identified pathways, Notch signalling modulation by ivabradine 
treatment may contribute this protection. Since numerous of these reported genes, 
including Notch, are shear stress modulated [115], our data are in agreement with the 
shared views that ivabradine, through heart rate reduction, modifies the shear stress on 
endothelium. 
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